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Abstract 
 
The main aim of the study in this thesis was to use structure-based protocols to 
design new drugs for enzymes, DXS and DXR in the non mevalonate pathway. Another 
aim of this study was to identify the dimer interface in E.coli FabH as an allosteric 
binding site for designing new class of anti-infective drugs. We have attempted to 
identify potential inhibitors for DXS by docking the NCI Diversity set compounds, 
compound libraries available from GSK-MMV and St. Jude’s Children’s research center. 
FabH dimer interface has been identified as a potential target using SiteMap, Alanine 
mutagenesis and docking studies. 
The first chapter gives an overview of the computational methods. The next two 
chapters briefly introduce the biological targets in the author’s study. Chapter two 
explains the importance of non-mevalonate pathway in microbes. Different enzymes in 
the non-mevalonate pathway are discussed and the importance of terpenoids in biological 
processes and also the use of terpenoids as drugs have been extensively discussed in this 
chapter.  The crystal structures available for DXS and DXR are also discussed. Chapter 
three brings out the importance of FabH as an anti-infective target. Crystal structure of 
FabH E.coli is discussed and the importance of FabH as a dimer has been discussed in 
this chapter. 
xi 
 
Chapter 3 describes the methods, homology models generated, and analysis from 
docking studies. The homology models for PvDXS and PvDXR have been used in this 
study to identify potential inhibitors. Domain swapping and the structural organization of 
PvDXS before and after domain swaping are discussed. Identification of domain swaping 
in PvDXS using entropy changes has been extensively discussed.  
Chapter 4 focuses on FabH (Fatty Acid Biosynthesis, enzyme H also referred to 
as β-ketoacyl-ACP-synthase III) dimer interface as an allosteric target. SiteMap analysis 
and MD simulations on the FabH monomer and dimer structures revealed the dimer 
interface as a binding region. Further analyses were done by mutagenesis studies on the 
Phe87 residue, a key residue at the dimer interface region and validating the results using 
docking studies. NCI Diversity Set compounds were docked at the dimer interface of 
FabH, which revealed that compounds NSC91529 and NSC19803 docked best at the 
dimer interface region with the phenyl ring of both the compounds  
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Chapter 1 
Infectious diseases 
Infectious diseases are caused by organisms such as bacteria, virus, fungi or 
parasites. Although many microorganisms colonize in our bodies, they prove harmless 
until certain conditions favorable to cause disease are encountered. Some infectious 
diseases can be transmitted from person to person, while some are transmitted via insect 
bites or contamination of food and/or water. Some infections could be prevented by 
vaccination while some others may be fatal. 
In the past, several antibiotics have been developed and successfully used to treat 
infectious diseases. However, many organisms have acquired resistance to these 
antibiotics, making them less effective, which proves the need to discover novel class of 
compounds to inhibit these organisms from causing the disease. Different approaches 
could be followed to find novel class of compounds as anti-infective agents. One 
approach is to directly target the microorganism and prevent it from causing the disease, 
which is the widely followed method in drug discovery. Since some pathogens exploit 
host-encoded factors for colonizing, the molecular target could be host encoded. In the 
latter approach, there is a significantly less chance of microbial resistance, but proves to 
be a difficult approach  
HIV, malaria and tuberculosis top the list of deaths caused by infectious diseases. 
Malaria is the second major killer of humans, which is responsible for about 250 million 
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deaths per year.
1
 In 2010, there were 216 million reported cases of Malaria and about 6.5 
million people were killed by this disease.
2
 It is endemic in over 90 countries with a 
population of 2.4 billion people, about 40% of the world’s population.1 Recurring 
antimicrobial resistance to the currently available drugs poses to be a threat. Discovering 
new molecular targets and new class of inhibitors prove to be vital to overcome the issue 
of microbial resistance to drugs.  
Major causative agents of malaria include Plasmodium vivax, Plasmodium 
falciparum, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, out of 
which Plasmodium falciparum and Plasmodium vivax are the most important for the 
pathogenesis of malaria.
3
 Plasmodium falciparum is deadly while Plasmodium vivax 
causes less severe complications but is more widespread, especially in the temperate 
zones. Plasmodium vivax can hibernate in the liver for months or years and can resurface, 
causing disease.
3
 All the Plasmodium species possess a non-photosynthetic organelle 
called the apicoplast, which is nuclear encoded.
4
 Important biochemical pathways 
required for organismal survival occur in the apicoplast. Exploring biochemical pathways 
present in the apicoplast but not in humans is an interesting way to finding new molecular 
targets for developing antimalarials. Non-mevalonate pathway, discovered about a 
decade ago is one such pathway which is present in all the intra-erythrocytic stages of 
Plasmodium but not in higher animals. Hence enzymes in this pathway prove to be 
alluring targets for anti-malarial drug discovery.  
The first enzyme of this pathway, DXS (1-deoxy-D-xylulose-5-phosphate 
synthase) catalyzes the rate limiting step of NMP pathway and is also essential for 
thiamine and pyridoxol biosynthesis.
5
 A direct approach to anti-malarial drug discovery 
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is to target this enzyme. Alternatively, the reaction catalyzed by the second enzyme of 
this pathway, DXR (1-deoxy-D-xylulose-5-phosphate reductoisomerase) forms the first 
committed step of NMP pathway and hence, DXR could serve as a molecular target for 
anti-malarial drug development. In this study, we have used DXS and DXR as molecular 
targets towards fining new inhibitors as antimalarials. 
Fatty acid biosynthesis is another interesting pathway, which follows entirely 
different mechanisms in humans and other lower organisms.
6
 Fatty acid biosynthesis is 
also present in the apicoplast of Plasmodium, making it a great malarial target.
7, 8
 An 
important enzyme in the fatty acid cycle of bacteria is FabH, which initializes the 
condensation reaction between malonyl ACP and acetyl CoA producing -keto acyl 
ACP.
9
 Fatty acid biosynthetic pathway, especially the enzyme FabH has already been 
proven to be an attractive target. FabH in many organisms exist and functions as a homo 
dimer. Several inhibitors that have been proposed as FabH inhibitors either lacked 
specificity for FabH or failed to reach the molecular target. Even the drugs that are 
developed to inhibit FabH in combination with other condensing enzymes are at a high 
risk of getting rejected by the microbes due to developing resistance.  
A direct way to approach the problem of microbial resistance is to find new class 
of inhibitors for the enzyme. An alternative yet interesting approach to target an enzyme 
is to explore allosteric sites, where disruptors could bind. Allosteric site of inhibition 
refers to an alternative site in the protein surface, where molecules can bind and 
significantly alter the activity of the enzyme. Since FabH functions as a dimer, we were 
interested in exploring the dimer interface as an allosteric target, which could reduce 
mutational resistance.
10
 Inhibitors targeting the dimer interface of HIV have already been 
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proposed,
11
 which proves that targeting the dimer interface could be an interesting 
approach to develop anti-infectives. In this study, we have proved the dimer interface of 
FabH to be a good molecular target through MD simulations and other analyses.  
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Chapter 2 
Enzymes in Non-Mevalonate Pathway as Anti-Malarials 
Isoprenoids 
Isoprenoids are terpernoid derivatives and are among the oldest known 
biomolecules that serve important biochemical functions. Biosynthesis of isoprenoids 
takes place by the condensations of isopentenyl diphosphate (IPP) and its isomer 
dimethyl allyl diphosphate (DMAPP). Two distinct pathways exist for the synthesis of 
isoprenoids; in algae and higher plants, isoprenoids are derived from IPP, which is 
synthesized by the condensation of pyruvate and glyceraldehyde-3-phosphate via the 
non-Mevalonate pathway (NMP); in mammals and other organisms, isoprenoid 
biosynthesis starts from acetyl CoA and proceeds via the intermediate mevalonic acid.  
Biological significance of isoprenoids 
Isoprenoids are biologically important compounds that have found profound uses 
in the pharmaceuticals and agrochemicals industry.
1
 All isoprenoids are derived from the 
common five carbon building units, IPP and DMAPP. Higher isoprenoids of increasing 
size are formed by addition of two or more IPP units and also addition of IPP to DMAPP. 
Some biologically important isoprenoids are listed in Table.1 
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Table 1. Biologically important isoprenoids 
Isoprenoids Significance 
 
Aucubin 
Iridoid-defensive compounds found in 
plants and animals. 
 
 
 
Geranyl pyrophosphate 
Used in the biosynthesis of farnesyl 
pyrophosphate, cholesterol, terpenes 
and terpenoids. 
 
Farnesyl pyrophosphate 
Intermediate in HMG-CoA reductase 
pathway; used in the biosynthesis of 
cholesterol, terpenes and terpenoids. 
 
Cholesterol 
Steroid essential for membrane 
permeability and fluidity in 
mammalian cell membranes. 
 
Vitamin E 
Fat soluble antioxidant that scavenges 
peroxyl radicals. 
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3-hydroxy-3-methylglutaryl-CoA 
(HMG-CoA) 
HMG-CoA reductase 
Mevalonic acid 
Mevalonate kinase 
Mevalonate-5-phosphate 
Mevalonate-5-pyrophosphate 
decarboxylase 
Phosphomevalonate kinase 
Isopentenyl-5-pyrophosphate 
Isopentenyl  pyrophosphate  
isomerase Dimethyl allyl 
pyrophosphate 
Acetyl-CoA 
Thiolase 
Acetoacetyl-CoA 
HMG-CoA 
synthase 
 
Mevalonate-5-pyrohosphate 
CO2 
ATP 
Non -Mevalonate Pathway (NMP) 
Mevalonate pathway was the only known pathway to synthesize IPP and DMAPP 
for several years until the NMP route was discovered in 1999 by Rohmer.
2
 NMP was 
discovered by a series of labeling experiments in bacteria and higher plants. 
Mevalonic acid pathway 
The mevalonic acid pathway (MVA) (Figure 1) in yeast and animals was found in the 
1950s and it was assumed to be the only pathway to synthesize IPP.
3
  
 
Figure 1. Biosynthesis of isoprenoid precursors via Mevalonic acid pathway  
In contrast to the NMP, biosynthesis of IPP and DMAPP in the mevalonic acid 
pathway starts with acetyl CoA and proceeds via the mevalonic acid intermediate. 
Following the discovery of the biosynthesis of specific isoprenoids in plants and 
microorganisms, the NMP pathway or the mevalonate independent pathway was 
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discovered by labeling experiments in bacteria and plants. However, archeabacteria, 
fungi and animals synthesize their isoprenoids using the MVA pathway, which suggests 
the presence of both pathways in plants, although they are localized in different 
compartments. Cytosolic IPP is produced by the MVA pathway while IPP and DMAPP 
in plastids are produced by the NMP pathway. An exchange of IPP between cytosol and 
plastids has also been reported. 
4
 
Mechanism of Non-Mevalonate Pathway 
The non-Mevalonate pathway involves a total of six enzymes to synthesize the 
isoprenoids IPP and DMAPP (Figure 2). The first step is the condensation reaction of 
glyceraldehyde 3 phosphate with pyruvate to produce 1-deoxy-D-xylulose-5-phosphate 
(DXP), catalyzed by 1-deoxy-D-xylulose-5-phosphate synthase (DXS). DXS has a 
cofactor, thiamine pyrophosphate (TPP) buried within the active site. This step is rate 
limiting to the production of IPP and DMAPP. Second step is the reduction of 1-deoxy-
D-xylulose-5-phosphate to 2C-methyl-D-erythritol-4-phosphate (MEP), catalyzed by 1-
Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR). This forms the first committed 
step of the non-mevalonate pathway. Fosmidomycin is an inhibitor of DXR with Ki of 38 
nM against E. coli, 28 nM against P. falciparum and 310 nM against M. tuberculosis. 
IspD catalyzes the reaction of MEP with cytidine triphosphate (CTP) to form 4-
diphosphocytidyl-2Cmethyl-D-erythritol (CDP-ME) and releases pyrophosphate. IspE, 
an ATP dependent enzyme catalyzes the conversion of CDP-ME to 4-diphosphocytidyl-
2C-methyl-D-erythritol-2-phosphate (CDP-ME2P). Enzyme IspF catalyzes the 
conversion of CDP-ME2P to the cyclic phosphate, 2C-methyl-D-erythritol-2,4-
cyclodiphosphate (MECP), releasing cytidine monophosphate (CMP). The 
10 
 
transformation of MECP to 2-methyl-2-(E)-butenyl diphosphate is catalyzed by IspG in a 
two-electron reduction while the enzyme IspH catalyzes the production of IPP and some 
DMAPP. 
 
Figure 2. Non-mevalonate pathway of isoprenoid biosynthesis 
Enzymes in Non-mevalonate pathway 
Individual enzymes in the non-mevalonate pathway are described below. 
DXS (1-deoxy-D-xylulose-5-phosphate synthase) 
The non-mevalonate pathway begins with the condensation of pyruvate and 
glyceraldehyde-3-phosphate catalyzed by the DXS enzyme. Thiamine pyrophosphate as a 
cofactor and a divalent metal cation like Mg
2+
 or Mn
2+
 is utilized in this reaction.
5
 The 
only crystal structures reported to date are from the organisms, E. coli and D. 
radiodurans. The DXS enzyme is a homodimer and has three distinct domains like 
11 
 
transketolase, which also catalyzes a similar reaction. However the domain arrangement 
is different in the two enzymes. In DXS, domain I lies on top of domain II and domain III 
of the same monomer, with the active-site at the domain I-II interface (Figure 3), while 
transketolase has the active-site at the dimer interface since domain I lies on top of 
domain II and domain III of the other monomer. In addition to catalyzing the above said 
condensation reaction, DXS is also responsible for the biosynthesis of thiamine and 
pyridoxol in E. coli, which implies that DXS may not be the only enzyme specific for the 
NMP.
6
 
It is also reported that DXS can use other sugar phosphates as well as short-chain 
aldehydes as substrates.
7
 Since the levels of several plastidial isoprenoids change in direct 
proportion to DXS level, this enzyme is reported to be the rate-limiting enzyme for 
IPP/DMAPP synthesis in plants. 
 
Figure 3. Crystal structure of DXS from D. radiodurans
8
 (PDB: 2o1x) 
Domain I 
Domain II 
Domain III 
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DXR/IspC (1-deoxy-D-xylulose-5-phosphate reductoisomerase) 
The enzyme DXR catalyzes the second step of NMP. The crystal structures 
available for DXR are from the organisms, E. coli, M. tuberculosis and Z. mobilis. DXR 
in E. coli is composed of three domains: an N-terminus that binds the cofactor NADPH, a 
central domain that contains many of the active-site residues, and a C-terminus (Figure 
4).
9
 There is a flexible segment in before the C-terminus which acts as a lid for the 
catalytic center. Similar to DXS, DXR also has a divalent Mn
2+
 ion bound to it.  
Fosmidomycin is an inhibitor of this enzyme with an IC50 of 24nM (Figure 4).
9
 
DXR catalyzes the committed step in the non-mevalonate pathway. 
 
Figure 4. Crystal structure of E. coli DXR in complex with Fosmidomycin
9
 (PDB: 
1Q0L) 
 
IspD (4-diphosphocytidyl-C-methyl-D-erythritol cytidyltransferase) 
IspD catalyzes the reaction of MEP with CTP to form 4-diphosphocytidyl-C-
methyl-D-erythritol (CDP-ME) and pyrophosphate is released in this reaction. This 
enzyme has a single domain surrounding a seven-stranded twisted -sheet, which has an 
13 
 
extended -arm.
10
 Active-site is formed at the dimer interface, which is formed by the 
association of the two -arms. 
IspE (4-Diphosphocytidyl-2C-methyl-D-erythritol Kinase) 
The enzyme IspE phosphorylates the 2-hydroxy position of 4-diphosphocytidyl-
C-methyl-D-erythritol. This reaction utilizes ATP and the divalent metal cation Mg
2+
. 
The enzyme subunits display a -fold characteristic of the GHMP (galacto-
homoserine-mevalonate-phosphomevalonate) kinase superfamily, with the catalytic 
center located in a deep cleft between the domains.
11
  
IspF (2C-Methyl-D-erythritol 2,4-diphosphate Synthase) 
IspF converts 4-diphosphocytidyl-2Cmethyl-D-erythritol 2-phosphate into a 
cyclic phosphate, 2C-methyl-D-erythritol 2,4-cyclodiphosphate, with the release of 
cytidyl monophosphate. This enzyme also requires either a Mn
2+
 or Mg
2+
 ion as a 
cofactor. The crystal structure reveals a homotrimer with Zn
2+
 ions coordinated by two 
conserved histidines and one aspartate residue.
1
 The Zn
2+
 ion is reported to position the 
substarte in the active-site and the Mg
2+
 ion is required for the coordination of  
phosphate groups of cytidyl diphosphate. 
IspG (2C-Methyl-D-erythritol 2,4-cyclodiphosphate Reductase) 
Enzyme IspG converts the cyclic phosphate formed in the previous step to 
1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate. Purified IspG genes from E. coli, when 
subjected to absorption spectroscopy revealed the presence of [4Fe-4S]
2+
 clusters, which 
is essential for catalysis formed by three conserved cysteine residues.
1
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IspH (1-Hydroxy-2-methyl-butenyl 4-diphosphate Reductase) 
This is the final step for the formation of IPP/DMAPP. Conversion of 
1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate to IPP/DMAPP is catalyzed by this 
enzyme. This enzyme requires NADH, FAD, and a divalent metal cation, preferably 
Co
2+
, as cofactors. Similar to IspG, IspH is also found to have a [4Fe-4S]
2+
 cluster.
5
 
Importance of NMP 
 Enzymes involved in the biosynthesis of isoprenoids are currently of vital interest, 
especially because they can be targeted for the design of novel inhibitors for broad 
spectrum anti-malarial drugs and other infectious diseases.
12
 Non-Mevalonate pathway is 
very suitable in this regard since it occurs in serious human pathogens, but is absent in 
mammals. Enzymes in pathways like NMP have a unique function like a specific 
substrate consumption or product generation that cannot be compensated for by another 
enzyme,
13
 which can be exploited in designing inhibitors. 
 Organisms that utilize exclusively NMP pathway or the mevalonic acid pathway
5
 
are summarized in Table 2. 
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Table 2. Organisms employing MVA/NMP for biosynthesis of isoprenoids 
  Mevalonate Non-mevalonate  
  Pathway pathway 
Bacteria 
Archea - 
Fungi - 
Algae 
Higher plants 
 
Plastids - 
Cytosol - 
Protozoa 
Animals - 
 
Apart from isoprenoid biosynthesis, the pathway is also responsible for thiamine 
and pyridoxol production.
14
 The NMP pathway is also responsible for the production of 
the precursors for the synthesis of cytokinins like trans-zeatin.
4
  
Some drugs that target the isoprenoid biosynthesis
12
 are listed in Table 3. 
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Table 3. Drugs that target isoprenoid biosynthesis 
Drugs Function 
 
Taxol 
Paclitaxel 
Used in cancer chemotherapy 
(source of IPP in biosynthesis of taxol) 
 
 
Lipitor 
Atorvastatin 
Used in lowering blood cholesterol 
(HMG-CoA reductase inhibitor) 
 
Fosamax 
Alendronic acid 
Used in osteoporosis and other bone 
diseases 
(Farnesyl diphosphate synthase inhibitor)) 
 
Non-mevalonate pathway enzymes as antibacterial targets 
Increasing problems of drug resistance in all microbial pathogens against the 
currently available antibiotics has raised the need to design new inhibitors against current 
and novel targets.
15
 The increasing occurrence of multi-drug resistant organisms further 
augment this problem. Hence, exploring new antibiotics targets and developing novel 
antibiotics has become a matter of maximum urgency. Improved medications need to be 
discovered that are effective against microbial species to provide effective treatment 
17 
 
without prolonged use. Targeting biochemical pathways that exist in bacteria but not in 
humans, presents an important strategy for antimicrobial drug design and development.
16
 
One such important pathway is the mevalonate/non-mevalonate pathway for isoprenoid 
biosynthesis. 
NMP as anti-malarial target 
Plasmodium species, the major causative agent of this deadly disease, have 
developed drug resistance against many of the currently available drugs, which triggers 
the need for development of new drugs that are not only effective but potent. Improved 
medications need to be discovered that are effective against the plasmodium species to 
provide effective treatment without prolonged use. Since Non-mevalonate pathway is 
present in all the intra-erythrocytic stages of Plasmodium, NMP proves to be an alluring 
anti-malarial drug target. 
Conclusion 
Terpenoid biosynthesis genes are very important for the pathogens as terpenoids 
cannot be acquired from the environment.
1
 A majority of the pathogenic bacteria use the 
non-mevalonate pathway as an exclusive way to synthesize isoprenoid precursors. Some 
gram positive bacteria like staphylococcus make use of the mevalonic acid pathway to 
synthesize isoprenoids.
17
 Some other organisms like monozytogenes utilize both of the 
pathways but with distinct compartmentalization.  
The presence of the non-mevalonate pathway in most microbial pathogens makes 
it an alluring target for many infectious diseases. Many infectious diseases including 
dengue, leishmaniasis, leprosy and Chagas disease have been reported in the WHO as 
neglected tropical diseases.
18
 Since DXS is present in most of the microbes that causes 
18 
 
these diseases, this pathway can provide an interesting drug discovery target for 
anti-infectious diseases. In conclusion, the DXS pathway enzymes are alluring targets for 
the design of novel anti-infective drugs.  
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Chapter 3 
FabH as a therapeutic target 
Introduction 
Infectious diseases cause about 13 million fatalities per year, accounting for 25% 
of deaths worldwide.
19
 A repercussion of excessive usage of antibiotics has been the 
development of resistance to almost every class of antimicrobials. Innovative techniques 
are required for development of novel antibiotics to overcome the problem of resistance 
against currently available drugs. 
Fatty acid biosynthesis has proven to be an alluring target for antibacterials. Fatty 
acid synthase, type II (FAS II) governs the synthesis of straight chain saturated and 
unsaturated fatty acids in archaeabacteria and eubacteria (Figure 5), while FAS I is 
employed by higher organisms for fatty acid biosynthesis. FAS II that generally is 
utilized by bacteria uses a more dissociated system, where nine separate polypeptides are 
involved that may be dimeric, tetrameric or have other higher order structure.
20
 A very 
important feature of FAS II is that the intermediates are transported through the 
cytoplasm by an acidic and highly conserved acyl carrier protein (ACP). FAS I has a 
similar carrier arm but is attached to the main polypeptide chain, which makes the 
intermediates in this pathway much less accessible to the other enzymes. FAS I and FAS 
II differ from one another and lack homology in the active sites, but their mechanisms of 
elongation and reduction are similar. Each of the discrete enzymes in FAS II can be 
compared to an equivalent domain in FAS I. The significant differences in structural 
23 
 
organization and role played by fatty acids between bacteria and humans make FAS II an 
opportune target for antibacterial drug discovery.
21
 
 
Figure 5. FAS II pathway; FAS II pathway involves nine different enzymes that 
catalyzes specific reactions. 
 
FabB, FabF and FabH (Fatty Acid Biosynthesis, enzyme H) are the condensing 
enzymes in FAS II that play an important role in the initiation and elongation of fatty acid 
chains. FabB and FabF use acyl-ACPs as primers while FabH uses acetyl-CoA as an acyl 
donor, which makes it unique among the FAS II condensing enymes.
22
 FabH also 
referred to as β-ketoacyl-ACP-synthase III, is a key condensing enzyme of the type II 
FAS system and is essential for the growth and survival of both Gram-positive and Gram-
negative bacteria. It has been extensively studied in E. coli although studies have been 
done in S. aureus
23
 and M. tuberculosis.
24
 FabH is ubiquitously expressed indicating that 
the enzyme has an important regulatory function and is essential for organismal 
24 
 
survival.
25
 Some small molecules have also been shown to inhibit FabH,
26, 27
 which 
supports the concept that FabH could be a good biomolecular target. FabH does not have 
any close homologue in humans and the architectural differences between human FAS I 
and bacterial FAS II make it an ideal candidate for the identification of novel,
28
 selective 
anti-bacterial drugs. 
FabH 
FabH functions as a homodimer, with a monomeric molecular weight of 35 kDa,
29
 
and is highly conserved among the key pathogens. FabH catalyzes the Claisen 
condensation reaction of malonyl-ACP with an enzyme-bound acetate unit (obtained 
from the reaction between acetyl-CoA and the catalytic residue, cysteine, with release of 
CoA) (Figure 6).
24
 The reaction product formed from FabH initiated reaction, undergoes 
chain elongation reactions in subsequent cycles catalyzed by FabF and FabB to produce 
long-chain acyl-ACP products.
24
 FabH, the initiation condensing enzyme of the FAS II 
pathway, is structurally distinct from the elongation condensing enzymes, FabF and 
FabB. 
 
Figure 6. Reaction catalyzed by FabH which catalyzes the Claisen condensation between 
malonyl ACP and a bound acetate unit derived from acetyl-CoA to form β-ketoacyl ACP. 
25 
 
Known inhibitors  
Cerulenin and thiolactomycin (Figure 7a and 7b) are two inhibitors that were 
discovered a couple of decades ago that target the condensing enzymes in the FAS 
pathway but exhibit poor antibacterial activities.
27
 Platencin (Figure 7c) is a dual inhibitor 
targeting FabH and FabF, and exhibits IC50 values of 9.17 µM and 4.58 µM towards S. 
aureus FabH and FabF, respectively.
26
 Other inhibitors targeting FAS II condensing 
enzymes identified in the past
30
 either failed to reach their intracellular targets or lacked 
target specificity.
27
 These inhibitors act within the active site, and the mode of action  has 
been extensively studied to develop a model for active-site inhibitor design.
31
 
 
Figure 7. Known inhibitors of FAS II enzymes: a. Structure of Cerulenin, a known 
inhibitor of FabF/FabB; b. Structure of Thiolactomycin, a known inhibitor that targets 
FabH and FabF/FabB; c. Structure of Platencin, a dual inhibitor for FabH and FabF. 
 
As shown crystallographically,
32
 The dimer surface buries about 3200 Å
2
 of 
surface area and plays an important role in substrate recognition. Dimer formation is 
important for proper functioning of FabH.
24
 The interface is primarily formed by residues 
in four loops: 84-86, 146-157, 185-217, 305-307; all of which are involved in the 
formation of the active site.
24
 Residues that are important for substrate binding include 
Trp32, Arg151, and Phe87 of the other monomer. Trp32 and Arg151 lie at the entrance of 
the active site
32
 (Figure 8). Residue Phe87 of one monomer projects into the binding 
26 
 
pocket of the other monomer and engages in van der Waals interactions with acetylated 
Cys112 and substrate, making it crucial in determining primer specificity.
24, 32
 The crystal 
structure of FabH in the apo form has also been solved
33
 and is reported to be disordered 
in the four loops that form the dimer interface.  An important observation reveals that 
Phe87 swings away from its ligand-bound position, and the side chain of Phe87 is 
disordered in apo FabH.
33
 These observations suggest that residue Phe87 has a significant 
role in stabilizing the active form of the dimer.  
 Dissociation constant (KD) for the monomer-dimer equilibrium in FabH was 
observed to be 1.00 ± 0.03 µM from ultracentrifugation studies and analytical gel 
filtration data,
33, 34
 which indicates weak dimerization compared to the dissociated 
monomers. 
Catalytic triad in FabH 
In FabH, the active site is composed of a catalytic triad formed by residues, 
Cys112, His244 and Asn274 (Figure 8).
33
 Residue Cys112 is involved in acetyl transfer 
while His244 and Asn274 play an active role in decarboxylation.
32
 Residues His244 and 
Asn274 are present close to Cys112 in the long active site tunnel. The active site 
residues, Cys112, His244 and Asn274 were mutated to alanine in a study by Davies et 
al.,
35
 which revealed that these residues are important for the activity of FabH enzyme. 
FabH enzyme has been reported to be a source of monomer generation for poly-hydroxy 
alkanoate (PHA) production.
36
 Several mutants on the Phe87 residue have been prepared 
mainly to test the activity of the PHA monomers generated, since the residue Phe87 plays 
an important role in the generation of short chain length and medium chain length PHA 
27 
 
monomers.
36
 But the importance of this residue in the dimer interface towards the activity 
of FabH has not been completely probed yet. 
Figure 8. Crystal structure of FabH (1HN9) shown as ribbon representation; important 
residues in the dimer interface region and active site are represented in cpk (space filling 
model): Phe87 (left); Trp32 and 151 (upper right); Cys112, His244 and Asn274 (lower 
right) (PDB:1HN9). 
 
In the recent years, structure-based molecular modeling has emerged as an 
important tool in the drug discovery process. Virtual screening and molecular dynamics 
are widely used tools in structure-based drug design; while virtual screening enables us to 
predict the binding mode of ligands to receptors; molecular dynamics is widely used to 
understand the structural dynamics and protein flexibility. For structure-based drug 
design of inhibitors, a thorough knowledge of the dimer interface is essential. Sharing 
28 
 
about 3200 Å
2
 surface area, the dimer interface is indeed a protein-protein interface with 
each monomer having a huge dimeric partner. Molecular dynamics and docking studies 
have been performed previously on FabH, but targeting the biological active site.
37
 
Although the dimer interface has been studied in FabH, very little is known about the 
conformational properties of the solvated monomers.  
Dimer Interface 
Targeting the dimer interface involves a protein-protein disruption, which covers 
a large surface area. Previously, it has been reported that in order to disrupt a protein-
protein interface, it is not necessary to target the entire interface region; it is only 
necessary to identify ‘hotspots’ at the interface region which comprises just a few 
residues that are important in the interface region.
38
 It is also known that small molecules 
or peptides that bind to one partner almost always compete with the natural protein 
partner to bind at the hotspot. This implies that tight binding using small molecules and 
or peptides could be achieved although the surface area covered by them would not be as 
large as the protein partner and several protein-protein disruptors have been identified in 
the past decade, that validate this concept
38
  
Importance of FabH in drug discovery 
FabB, FabF and FabH are the condensing enzymes in FAS II that are important in 
the initiation and elongation of the fatty acid chains. Acyl-ACPs are used as primers in 
FabB and FabF while acetyl-CoA is used as an acyl donor in FabH, which makes it 
unique among the FAS II condensing enymes.
22
 Primer specificities of FabH in different 
organisms seem to be the determining factor in production of either straight or branched 
chain fatty acids.
39
 FabH is ubiquitously expressed indicating that the enzyme has an 
29 
 
important regulatory function and is essential for organismal survival.
25
 Many chemical 
entities have also been shown to inhibit FabH, which supports the idea that FabH could 
be good bio molecular target. Moreover, the architectural differences between human 
FAS I and bacterial FAS II
28
 make it an ideal candidate for the identification of novel 
anti-bacterial drugs. 
FabH as a therapeutic target 
FabH is an important enzyme in the fatty acid synthase pathway, which is 
conserved amongst the key pathogens.
26
 Inhibitors that target the enzymes of fatty acid 
biosynthesis have already been proven to be useful therapeutics. Although many 
antibacterial drugs exist, resistance to these drugs in most of the pathogenic bacteria 
emerges constantly. This poses a serious threat. It is therefore necessary to discover new 
inhibitors as well as new bacterial targets. Since FabH serves as a key regulator of the 
FAS II pathway, FabH could be considered an important anti-bacterial target. 
FabH as an antimalarial target  
The apicoplast is an essential organelle in all malarial parasites, which is thought 
to be of prokaryotic origin. Interesting pathways exist in the apicoplast of P. falciparum 
including non-mevalonate pathway for isoprenoid biosynthesis, ferredoxin-dependent 
electron transport, lipoate synthesis, iron-sulfur cluster formation, several steps of heme 
synthesis and de novo fatty acid synthesis.
40
 Since the FabH enzyme is a key regulator in 
the fatty acid synthesis pathway, which is present in the apicoplast of P.falciparum, FabH 
could be considered a good target to design antimalarials. Identification of P.falciparum 
-ketoacyl-ACP synthase III (PfKASIII) gene in P.falciparum indicated the presence of 
type II FAS in this parasite.
40
 PfKASIII and E.coli FabH share 35% sequence identity and 
30 
 
exhibit conservation among the catalytic residues Cys, His and Asn in the active-site, 
indicating that these structures have similar secondary structure in the active-site. E.coli 
FabH uses acetyl-CoA as substrate while PfKASIII uses butyryl-CoA as substrate, 
indicating its function in chain elongation and initiation.
41
  
Conclusion 
Targeting the dimer interface in FabH would open up entirely new class of 
pharmacophores and could also be used to tackle the problem of microbial resistance to 
existing drugs. Here, we present molecular dynamics simulations targeted at 
understanding the structure and conformational mobility of the solvated monomers 
compared to the dimer in solution. This study is based on the assumption that the 
interface conformation does not necessarily correspond to the conformation shown by the 
solvated monomers. The primary objectives of our study were to study the interface 
region and analyze the hydrophobic pocket occupied by Phe87 as a hot spot through MD 
simulations and collect trajectory snapshots for further analyses and perform docking 
studies with potential small molecule disruptors. Docking studies were performed using 
the database of compounds available from the National Cancer Institute. We used the 
NCI Diversity Sets I and II for this study.  
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Chapter 4 
Inhibitor design for Plasmodium vivax DXS and DXR  
Introduction 
Enzymes in the non-mevalonate pathway have been proven as useful therapeutics. 
The absence of these enzymes in mammals point towards this pathway as an alluring 
target for the discovery of antimalarials. Secondary structure information is critical to 
design and develop new inhibitors targeted against any enzyme. Absence of crystal 
structures for the plasmodium species in DXS, the first enzyme in non-mevalonate 
pathway and DXR, the second step and the first committed step of the non-mevalonate 
pathway hinder the process of finding new drugs targeting these enzymes. Hence, the 
development of homology models is critical to derive sufficient information about the 
overall structure of the enzymes and the active-site. To date, there are only two crystal 
structures reported for DXS; they are from the organisms E. coli and D. radiodurans. For 
DXR, several crystal structures have been reported from organisms, E. coli,
1
 Z.mobilis
2
, 
M.tuberculosis,
3
 and P.falciparum.
4
 
In the absence of available crystal structures, our aim was to develop a homology 
model of PvDXR, P. vivax being one of the important causative agents of malaria.  
Although P. falciparum causes severe complications, infections due to P. vivax are 
widespread and the organism lays dormant in the liver, causing the disease to resurface 
after many years.  
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The homology model would give us insight into the structural features of PvDXR 
and its likely binding to ligands and cofactors, which would aid structure-based inhibitor 
design. To accomplish this goal, initial models were generated for PvDXR using the 
Prime module of Schrodinger Suite. The model was refined using energy minimization 
procedures, Impact and MacroModel of the Schrodinger suite and was further validated 
by Procheck. A protein-ligand complex was also generated using information available 
about known ligands. The developed model proved to be consistent with the available 
protein structures for EcDXR. This study should prove useful in the design and 
development of novel and potentially therapeutic inhibitors for PvDXR by either virtual 
screening or de novo design.  
The 3-D structure of an enzyme can be developed using comparative modeling 
based on the knowledge of previously available crystal structures. Several crystal 
structures of DXR from E. coli and other organisms have been reported to date.
1, 3-5
 DXR 
is a flexible enzyme made up of three domains: a C-terminal domain, a connecting 
domain which occupies the active-site loop, and the N-terminal dinucleotide binding 
domain.
6
 The C-terminal domain moves with respect to the other two domains upon 
binding of the cofactor and the substrate in the binding pocket. Even the active-site could 
exist in different conformations.
7
 Some crystal structures have the cofactor and a divalent 
metal cation present in the active-site along with the inhibitor; PDB 1Q0l for EcDXR has 
fosmidomycin present in the binding pocket and NADPH in the cofactor binding pocket 
along with manganese in its divalent state.
1
 The enzyme can exist in an open state (PDB 
1K5H)
5
 or the closed state (PDB: 1Q0L); the latter shows tight binding since the 
substrate and the cofactor binding pocket are occupied.  
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The crystal structure of D. radiodurans DXS is a dimer and has three domains; 
domain I lies entirely on top of domain II and domain III of the same monomer. The 
active site is located within the same monomer, between domain I and domain II. 
However, the crystal structure has some missing residues that connect domain I with 
domain II (linker). The crystal structure of E. coli also has three domains, with domain I 
lying on top of domain II and domain III of the same monomer. It also has some missing 
residues in the same region as D. radiodurans, the linker that connects domain I to 
domain II. 
Comparative modeling for PvDXR 
Alignment of sequences is a crucial step in building a homology model to create a 
connection between the reference and the target proteins. Hence it is important to 
thoroughly inspect the sequences, especially in the conserved regions. Multiple sequence 
alignment of PvDXR with sequences of E. coli (PDB ID: 1Q0L), P. falciparum, P. vivax, 
P. knowlesi, and P.berghei obtained from ClustalW 2.0.12
8
 are shown in Figure 9. The 
aligned structures were manually inspected and edited to reflect the structurally 
conserved regions of the available crystal structure of E. coli. The tertiary structure of the 
two proteins can be considered similar, since they share a significant degree of similarity, 
with a sequence identity of 39%. Medium-accuracy comparative models are based on 30-
50% sequence identity.
9
 
pfal            AIKKP--------INVAIFGSTGSIGTNALNIIRECNKIENVFNVKALYVNKSVNELYEQ 124 
pyoelli         SQNKP--------INVGIFGSTGSIGTNTLSIIRECNKIEKKFNVEALYVNKNVEGIYEQ 129 
pvivax          PSNRANRANPANCINVAIFGSSGSIGANALDVIRECNRVERRFNVEALYVNKSVTKLYEQ 162 
pknowlesi       SANTGNDATP---INVAIFGSSGSIGTNALDIIRECNRTQKRFNVEALYVNKSVNKLYEQ 153 
ecoli           --MKQ----------LTILGSTGSIGCSTLDVVRHN---PEHFRVVALVAGKNVTRMVEQ 45 
athaliana       DGPKP----------ISIVGSTGSIGTQTLDIVAEN---PDKFRVVALAAGSNVTLLADQ 124 
                               : *.**:**** .:*.:: .       *.* ** ....*  : :* 
 
pfal            AREFLPEYLCIHDKSVYEELKELVKNIKDYKPIILCGDEGMKEICSSNSIDKIVIGIDSF 184 
pyoelli         AKEFLPKYVCIHDPSKYEELKKLLENIKNYNPIILIGNEGMKQICSSNEIDKIVIGIDSF 189 
pvivax          AREFLPKYVCIHDESKYEELKMLLRKIKGYNPEILVGDDGMKQMCSSNTLDRIIIGIDSF 222 
41 
 
Figure 9 continued 
pknowlesi       AREFLPKYVCIHDESKYEELKNLLKNIKGYNPEILIGDEGMKQMCKSDTLDKVVIGIDSF 213 
ecoli           CLEFSPRYAVMDDEASAKLLKTMLQQQ-GSRTEVLSGQQAACDMAALEDVDQVMAAIVGA 104 
athaliana       VRRFKPALVAVRNESLINELKEALADL-DYKLEIIPGEQGVIEVARHPEAVTVVTGIVGC 183 
                  .* *    : : :  : **  : .  . .  :: *::.  ::.       :: .* .  
 
 
pfal            QGLYSTMYAIMNNKIVALANKESIVSAGFFLKKLLNIHKNAKIIPVDSEHSAIFQCLDNN 244 
pyoelli         QGLYSTIYAIKNNKTIALANKESIVSAGFFLKKLLTVHKNSTIIPVDSEHNAIFQCLNNN 249 
pvivax          HGLYSTIYAIKSNKIIGLANKESIVSAGFFLKKLLTSHTKSCIIPVDSEHSAIFQCLDNN 282 
pknowlesi       YGLYSTIYAIKNNKIIALANKESIVSAGFYLKKLLTIHTKSCIIPVDSEHSAIFQCLDNN 273 
ecoli           AGLLPTLAAIRAGKTILLANKESLVTCGRLFMDAVKQS-KAQLLPVDSEHNAIFQSLPQP 163 
athaliana       AGLKPTVAAIEAGKDIALANKETLIAGGPFVLPLANKH-NVKILPADSEHSAIFQCIQG- 241 
                 ** .*: **  .* : *****:::: *  .    .   :  ::*.****.****.:    
 
 
pfal            KVLKTKCLQDNFSKINNINKIFLCSSGGPFQNLTMDELKNVTSENALKHPKWKMGKKITI 304 
pyoelli         ILLKSKCLQENYSKINQINKIFLCSSGGPFQNLSIDELKNVSSEKALKHPKWNMGKKISI 309 
pvivax          KVLKTKCLQDSFSKVNQIKKLILSSSGGPFQNASLDELKKVTAEDALKHPKWKMGPKITI 342 
pknowlesi       KVLQTKCLQDNFSKVNQIKKIILSSSGGPFQNMSIDQLKNVTSADALKHPKWKMGPKITI 333 
ecoli           ---IQHNLGYADLEQNGVVSILLTGSGGPFRETPLRDLATMTPDQACRHPNWSMGRKISV 220 
athaliana       ------------LPEGALRKIILTASGGAFRDWPVEKLKEVKVADALKHPNWNMGKKITV 289 
                               . : .::* .***.*:: .: .*  :.  .* :**:*.** **:: 
 
pfal            DSATMMNKGLEVIETHFLFDVDYNDIEVIVHKECIIHSCVEFIDKSVISQMYYPDMQIPI 364 
pyoelli         DSATMMNKGLEVIEAHFLFDIDYNDIEIIVHKECIMHSCVEFLDKSVISQMYYPDMRVQI 369 
pvivax          DSATMMNKGLEVIEAHFLFDVDYNHIEILVHKECILHSCVEFIDKSVVSQMYLPDMKLPI 402 
pknowlesi       DSATMMNKGLEVIEAHFLFDIDYNNIDIVVHKECILHSCVEFIDKSVIAQMYYPDMKIPI 393 
ecoli           DSATMMNKGLEYIEARWLFNASASQMEVLIHPQSVIHSMVRYQDGSVLAQLGEPDMRTPI 280 
athaliana       DSATLFNKGLEVIEAHYLFGAEYDDIEIVIHPQSIIHSMIETQDSSVLAQLGWPDMRLPI 349 
                ****::***** **:::**. . ..:::::* :.::** :.  * **::*:  ***:  * 
 
pfal            LYSLTWPDRIKT---NLKPLDLAQVSTLTFHKPSLEHFPCIKLAYQAGIKGNFYPTVLNA 421 
pyoelli         IYALTWPNRINT---NLKSLNFEEISPLTFYKPSLKHFPCINLAYHAGRKSNFFPTVLNA 426 
pvivax          LYALTWPNRIAT---ELPSLNLASTSPLTFYSPSLDHFPCIKLAYQAGRQGNFYPTVLNA 459 
pknowlesi       LFGLSWPNRINT---DLPSLNLVNTSPLTFSSPSLDHFPCIKLAYHAGRKGTFYPTVLNA 450 
ecoli           AHTMAWPNRVNS---GVKPLDFCKLSALTFAAPDYDRYPCLKLAMEAFEQGQAATTALNA 337 
athaliana       LYTMSWPDRVPCSEVTWPRLDLCKLGSLTFKKPDNVKYPSMDLAYAAGRAGGTMTGVLSA 409 
                 . ::**:*:         *:: . ..***  *.  ::*.:.**  *   .   . .*.* 
 
pfal            SNEIANNLFLNNKIKYFDISSIISQVLESFNSQKVSENSEDLMKQILQIHSWAKDKATDI 481 
pyoelli         SNEVVNNLFLNNKIKYFDIPAIISQVLESFNPQQISENPEDLMKQILEIHNWSKQKAVDI 486 
pvivax          ANEVANKLFLSNKIGYFDIAAIISDVLESFTPQEVSNNCEDLMHQIGGIHKWAVRRAEEV 519 
pknowlesi       ANEVANKLFLNNKIGYFDIAAIISDVLESFTPQTISNNCEDLMKQIGDISNWSMEKATEV 510 
ecoli           ANEITVAAFLAQQIRFTDIAALNLSVLEKM--DMREPQC---VDDVLSVDASAREVARKE 392 
athaliana       ANEKAVEMFIDEKISYLDIFKVVELTCDKHRNELVTSPS---LEEIVHYDLWAREYAANV 466 
                :** .   *: ::* : **  :   . :.   :         :.::      :   * .  
pfal            YNKHNSS---- 488 
pyoelli         YNTKITS---- 493 
pvivax          YRVRSSAAQ-- 528 
pknowlesi       YQTRYGRMQ-- 519 
ecoli           VMRLAS----- 398 
athaliana       QLSSGARPVHA 477 
 
Figure 9. Multiple sequence alignment of DXP reductoisomerase of P. falciparum, P. 
yoelli, P. vivax, P. knowlesi, E. coli, A. thaliana  using ClustalW; The consensus 
sequence characterizes identical residues as ‘*’, strongly similar residues as ‘:’ and 
weakly similar residues as ‘.’; Insertions specific to plasmodium species are shown in red 
boxes, Insertion specific to plant homologues is shown in blue box. 
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The 3-D structure of PvDXR was generated using the Prime
10
 module of the 
Schrödinger Suite 2010. The model was generated using the tightly bound conformation 
of DXR in E. coli assuming it should be logically closer to the conformation adopted by 
the enzyme with substrate and co-factors present in a physiological environment. Since 
the C-terminus and the N-terminus do not contribute significantly toward ligand 
binding,
11
 some residues in these regions were truncated while building the model. An 
initial model of P. vivax DXP reductoisomerase was constructed using Prime comparative 
modeling module, including the coordinates of fosmidomycin and NADPH from the 
template of E. coli (PDB: 1Q0L). The constructed model was prepared by correcting 
bond orders, assigning protonation states and performing energy minimization until the 
heavy atoms RMSD converged to 0.3 Å relative to the starting geometry. PROCHECK 
3.5.3
12
 was used to validate the constructed model.  
The preparatory step was crucial to relieve any steric clashes and correct improper 
geometries in the protein structure. A protein-ligand complex is essential to understanding 
the interactions and structural complementarities between the ligand and the active site of 
the enzyme. Hence, the coordinates of fosmidomycin and the cofactor NADPH were 
retained while generating the homology model. Since the coordinates of the divalent 
metal cation was not present in the chosen template, coordinates of Mg
2+
 ion were 
obtained from PDB 2EGH, crystal structure of EcDXR with fosmidomycin and Mg
2+
. 
While retaining the coordinates from the template, it was assumed that the ligand binding 
modes are similar in the model and the template. Energy minimization was performed on 
the protein-ligand complex using MacroModel.
13
 The initial model was minimized to 
produce a better model for docking studies. The structure was minimized using 
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Macromodel; limited memory Broyden–Fletcher–Goldfarb–Shanno algorithm15 with 
OPLS_2005 forcefield.
16
 Macromodel minimization was performed for 500 iterations and 
a gradient convergence threshold of 0.1 Å.  
The RMSD between the initial model and the minimized model was found to be 
0.89 Å, while the RMSD between the initial model and the template was 0.24 Å, which 
suggests that the protein has not changed much with respect to the template. The small 
RMSD suggests a common structural homology between the model and the template and 
it can be inferred that the generated model is reasonable. The initial model and the 
resulting model after minimization are shown in Figure 10. 
 
Figure 10. Homology model of PvDXR; 10a. Initial model (green) superimposed on the 
MacroModel minimized structure (maroon); 10b.  Homology model of PvDXR (blue) 
superimposed on EcDXR Crystal structure (purple). 
 
The E. coli DXR enzyme is a homo dimer with three domains in each monomer.
5
 
The crystal structure of E. coli DXR consists of three domains: a C-terminus, a 
connective domain which contains the active site and an N-terminal domain. The 
C-terminus is made up of an α-helix and a β-strand and the connecting loop is comprised 
of six α-helices and six parallel β-strands and a loop that connects to the N-terminus. The 
10b 10a 
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N-terminal end is made up of seven α-helices and an anti-parallel β-sheet. A comparison 
of the active sites of the target and the template is shown in Figure 11. The active site 
residues S186, S222, N227, K228, Q231 in EcDXR (S308, S344, N349, K350, Q353 in 
PvDXR) lie within the connecting domain as proposed in the crystal structure of 
EcDXR.
1
 
 
Figure 11. Active site of the PvDXR showing the key residues (Right); Active site of the 
EcDXR crystal structure showing the key residues (left). Fosmidomycin is represented as 
ball and stick and carbons colored lime green; NADPH is represented as tube and carbons 
colored orange. 
 
The catalytic loop and the nicotinamide moiety of NADPH are required for 
correct positioning of the active site. Other structurally significant residues, namely 
W334, M336, M398, H272, H331, H379 and P396 in PvDXR (W212, M214, H153, 
H209, H257 and P274 in EcDXR), perform a vital role in the formation of the active site 
architecture.
7
 From Figure11, it is apparent that the architecture of the active sites in both 
the template and the model are quite similar and the active site residues have very similar 
orientations. However, there is a difference in the hatch residues N211 and S213 (in 
EcDXR), which have been replaced by lysine residues in PvDXR. In both the cases, the 
residues (K333 and K335 in PvDXR and N211 and S213 in EcDXR) lie within 7.7 Å of 
the ligand fosmidomycin, which suggests that there are no direct interactions possible 
with these residues. Comparison of the P. vivax DXR sequence with other plasmodium 
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species of DXR revealed insertions that were not present in bacterial species. The 
insertions were found at residues 139-141, 293-302, 491-493 in P. vivax DXR (Figure 9). 
 The cofactor NADPH has hydrogen bonding interactions with the following 
residues: E244, S124, S155, K154, N153, S126, I127 and M336 in PvDXR and residues 
T10, S12, I13, G36, K37, N38, K125, 126 and G215 in EcDXR. The major difference in 
the hydrogen bonding pattern is that the place occupied by T10 residue in EcDXR is 
occupied by S124 in PvDXR. These interactions provide evidence that NADPH has a 
vital role in tight binding of the inhibitor within the enzyme active site. 
The minimized structure was assessed for overall geometric quality (compared to 
known X-ray crystal structures) using Procheck.
12
 Procheck checks the stereo chemical 
quality of a given protein structure by verifying the accuracy of parameters like bond 
angles, bond lengths, torsion angles and correctness of amino acid chirality. Using these 
criteria, the PvDXR model compares well with the available X-ray crystal structure of 
EcDXR.  
 An important indicator of the stereo chemical quality of the model is the 
distribution of the main chain torsion angles phi and psi, which can be examined using a 
Ramachandran plot.
12
 Figure 12 shows the Ramachandran plots of the homology model 
of PvDXR. The plot clearly shows that the vast majority of the residues are in a phi-psi 
distribution consistent with right handed α-helices. The remaining residues that fall into 
the random or beta configuration geometries are small segments and are primarily present 
in the loop regions of the protein, remote to the active site.  
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Plot Statistics 
PvDXR 
(No 
minimization) 
PvDXR 
(Minimization) 
EcDXR 
Residues in most favored regions [A,B,L] 334 88.4% 334 88.4% 332 93.0% 
Residues in additional allowed regions 
[a,b,l,p] 
33 8.7% 36 9.5% 24 6.7% 
Residues in generously allowed regions 
[~a,~b,~l,~p] 
8 2.1% 4 1.1% 1 0.3% 
Residues in disallowed regions 3 0.8% 4 1.1% 0 0.0% 
 
Figure 12. Ramachandran plot of initial model of PvDXR (right) and PvDXR model 
after MacroModel minimization (left); (Below) Ramamchandran plot statistics for 
PvDXR homology model and EcDXR crystal structure. 
 
In addition to the Ramachandran plot, Procheck generated information about 
residues that deviated from planarity. Figure 13 shows the list of residues in which the 
planar groups have RMS deviation of more than 0.02Å or rings that have more than 
0.03Å from planarity. In order to correct the deviation and make a better model for 
docking purposes, the initial model constructed was minimized further using 
MacroModel. After MacroModel minimization, it was found that the Ramachandran plot 
had not changed much in terms of the residues in the favorable regions. However, the 
residues in the unfavorable regions have been reduced considerably from 2.9% (11 
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residues in total) overall to 2.2% (8 residues in total) after the minimization. Also the 
residues that had deviations from planarity in the initial model have been corrected after 
the minimization except for the two residues shown in Figure 13b. Even for the residues 
shown in Figure 13b, the deviations have reduced by a greater degree compared to the 
initial model. This suggests that the homology model developed after minimization is a 
better one compared to the initial model.  
 
 
 
 
 
Figure 13. Residues deviated from planarity for PvDXR model; 13a. Residues deviated 
from planarity after initial model construct; 13b. Residues deviated from planarity after 
MacroModel minimization on the initial construct. 
 
Docking studies of PvDXR 
Docking studies were performed with the MacroModel minimized homology 
model of DXR P. vivax. Virtual screening was performed using the diversity set II, 
available from the National Cancer Institute. Docking the ligands fosmidomycin and its 
derivative FR900098 with the homology model of PvDXR showed binding energies
14
 of 
-6.92 and -6.61 kcal/mol respectively and the RMS deviations from the original ligands 
were only 2.0807 and 2.050 Å, respectively. For E. coli DXR, the binding energies for 
fosmidomycin and FR900098 were –7.85 and –7.15 kcal/mol with RMS deviations of 
1.4997 and 1.4168 Å, respectively. Thus it is evident that the ligands that are found to be 
efficient in inhibiting DXR lie in the expected region in the generated model. This further 
13a 13b 
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validates the homology model constructed for P. vivax and provides a novel methodology 
for virtual screening studies. 
 
 
Figure 14. Ligand interaction diagram for binding of FR90098; 14a. Ligand interaction 
diagram for FR90098 with residues of PvDXR; 14b. Ligand interaction diagram for 
FR90098 with residues of EcDXR. 
 
Upon docking the NCI diversity set II, the top scoring compounds were identified 
by generating only a single pose for each ligand on the basis of glide score. The top 
scoring compound NSC70980 had a glide score of -12.28 kcal/mol (Figure 14a and 14b), 
which is ~4 kcal/mol lower than the score for fosmidomycin, which in turn suggests 
tighter binding to the receptor. The structure of the compound NSC70980 (glide score: -
12.29 kcal/mol) is shown in Figure 15.  
 
14a 14b 
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Figure 15. Binding of compound NSC70980 to PvDXR; 15a. Structure of compound 
NSC70980; 15b. a close-up view of compounds NSC70980 and fosmidomycin docked to 
PvDXR, 15c. compounds NSC70980 and fosmidomycin superimposed in the active site 
of PvDXR, also present is the cofactor NaDPH. 
 
Homology models were also developed for DXR from P. falciparum, Y. pestis 
towards the goal of developing new inhibitors for other infectious diseases as well, as 
reported in the WHO infectious diseases factsheet. We have also virtually screened the 
NCI diversity set II compounds to establish ‘hits’ for the target enzymes.  
 As DXR is the first committed enzyme in the NMP pathway for the biosynthesis 
of isoprenoids, targeting DXR in many organisms will prove important to find inhibitors 
for many infectious diseases. 
Comparative modeling of Plasmodium DXS 
The sequence of PvDXS and other Plasmodium DXS sequences were obtained 
from PUBMED and were aligned with the sequences of E. coli and D. radiodurans, the 
available crystal structures for DXS. The aligned structures were manually inspected for 
any anomalies and corrected to reflect the structurally conserved regions.  
 
 
 
15a 15b 15c 
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Table 4. Alignment scores between different organisms of DXS 
Sequence 1  Sequence 2  Alignment Score  
D.radiodurans  P.berghei  28 
D.radiodurans  P.knowlesi  28 
D.radiodurans  P. vivax  29 
E.coli  P.knowlesi  29 
D.radiodurans  P.falciparum  30 
E.coli  P.berghei  30 
E.coli  P. vivax  30 
E.coli  P.falciparum  31 
D.radiodurans  E.coli  45 
P.falciparum  P.knowlesi  50 
P.falciparum  P. vivax  50 
P.berghei  P. vivax  56 
P.berghei  P.knowlesi  57 
P.falciparum  P.berghei  63 
P.knowlesi  P. vivax  74 
    Templstes used are show in red 
The sequence of DXS P. vivax has 1111 residues, which was obtained from NCBI 
protein sequence database (http://www.ncbi.nlm.nih.gov). The PvDXS sequence was then 
aligned with the sequences of previously resolved crystal structures for DXS, E. coli and 
D. radioduran;, the alignment scores of which are shown in table 4. Multiple sequence 
alignment of PvDXS with sequences of E. coli (PDB ID: 201S), D. radiodurans (PDB 
ID: 201X) and P. falciparum was performed using ClustalW 2.0.12
8
  in the domain linker 
regions as shown in Figure 16. The aligned structures were manually inspected and edited 
to reflect the structurally conserved regions of the available crystal structures. The tertiary 
structure of the three proteins can be considered similar, since they share a significant 
degree of similarity, with a sequence identity of 32% and 29% respectively. Medium-
accuracy comparative models are based on 30-50% sequence identity.
9
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Pknowlesi       LFTVKNEDTQTGKEAQ----FITRAKKSD------------------------------D 242 
Pvivax          LFNVKNEEGQTGREPQ----LSGANEKSD------------------------------D 246 
Pfal            FDDYTNNNALYESEKKEYITLNNNNKNNNNKNNDNKNNDNNDYNNNNSCNNLGERSNHYD 294 
Pberghei        LGDTTNSGNIFS----------NNDKTNN-----------------------------YE 27 
Drad            ------------------------------------------------------------ 
Ecoli           ------------------------------------------------------------ 
                                                                             
 
Pknowlesi       AKDPPN------------LDAIFDQINSYLDIEKYKDSYGEEVYNQIVKLYVHRHVPENY 290 
Pvivax          NRDPPN------------LDALFDQINSYIDVEKYRDTYGEEIYHKMVKLYVRRDVPENY 294 
Pfal            NYGGDNNNPCNNNNDKYDIGKYFKQINTFINIDEYKTIYGDEIYKEIYELYVERNIPEYY 354 
Pberghei        NYNGNN------------LDRYFDEINKYINVDIYKNKYGEEIYNEIVNLYVKRDIPKNY 75 
Drad            ------------------------------------------------------------ 
Ecoli           ------------------------------------------------------------ 
                                                                             
 
Pknowlesi       KGGGN--PTQQSSYPGRNNLADHLNKVHIAIIGDGGLTGGMALEALNYISFLNSKVLIIY 588 
Pvivax          NRGG---TTQQSAYPGRNNSADHLNKVHIAIIGDGGLTGGMALEALNYISFLNSKVLIIY 585 
Pfal            INPSDVVGRENTNVPNVRNDNHNVDKVHIAIIGDGGLTGGMALEALNYISFLNSKILIIY 654 
Pberghei        --------------------NCTPNKFYISIIGDGGLTGGMALEALNYISFLNSKVLIIY 329 
Drad            ----------------------GKDFHVAAVIGDGSLTGGMALAALNTIGDMGRKMLIVL 180 
Ecoli           ----------------------GKNRRTVCVIGDGAITAGMAFEAMNHAGDIRPDMLVIL 178 
                                        :    .:****.:*.***: *:*  . :  .:*::  
 
Pknowlesi       NDNGQVSLPTNAPSIS------------------GHRPIGSISDHLRSFITR-KSGKGDS 629 
Pvivax          NDNGQVSLPTNAPSIS------------------GHRPIGSISDHLHSFLAR-KSGKGES 626 
Pfal            NDNGQVSLPTNAVSIS------------------GNRPIGSISDHLHYFVSNIEANAGDN 696 
Pberghei        NDNRQVSLPTNGKCIS------------------GNKPIGAISDHLYDFVKKNGKIIGKS 371 
Drad            NDN-EMSISENVGAMNKFMRGLQVQKWFQEGEGAGKKAVEAVSKPLADFMSR---AKNST 236 
Ecoli           NDN-EMSISENVGALNNHLAQLLSGKLYSSLREGGKKVFSGVP-PIKELLKR---TEEHI 233 
                *** ::*:. *  .:.                  *:: . .:.  :  :: .         
 
Pknowlesi       QNSSDKEKNNFFENLNYDYVQVQNGNNTEALFNVLSSFKKGSMNRATVLHVCTNKTSEFI 689 
Pvivax          QQASGTKKNNIFENLNYDYVQVQNGNDTEALFNALSAFKKGKMNRATVLHVCTSKTSDFI 686 
Pfal            KLSKNAKENNIFENLNYDYIGVVNGNNTEELFKVLNNIKENKLKRATVLHVRTKKSNDFI 756 
Pberghei        NINESDKNQNIFTNINYNYIGPIDGNNIENVIKILEDIKNKGIQKSTILHILTKKSSDFI 431 
Drad            RHFFDPASVNPFAAMGVRYVGPVDGHNVQELVWLLERLVD--LDGPTILHIVTTKGKGLS 294 
Ecoli           KGMVVPGTL--FEELGFNYIGPVDGHDVLGLITTLKNMRD--LKGPQFLHIMTKKGRGYE 289 
                .          *  :.  *:   :*::   :.  *. : .  :. . .**: *.*      
 
Pknowlesi       NSRAPITVMHSIKKNEIFPFNVDMLSSDGQKVKSPEPTAHSQ-------DDKMYSGKSPP 742 
Pvivax          NARAPITVMHSIKKNEIFPFSEDALSPHGKEGESAGHTAHAQ-------DDQANRGKSNF 739 
Pfal            NSKSPISILHSIKKNEIFPFDTTILNGNIHKENKIEEEKNVSSSTKYDVNNKNNKNNDNS 816 
Pberghei        NSKSPINIMHSIKKNEIFKFNLEELDSCHEEDNNINEQ------------SKKEDNEKNY 479 
Drad            YAEADPIYWHGPAKFDPATGEYVPSS---------------------------------- 320 
Ecoli           PAEKDPITFHAVPKFDPSSGCLPKSSG--------------------------------- 316 
                 :.      *.  * :         .                                   
 
Figure 16. Multiple alignment of DXS of P. knowlesi, P. vivax, P. falciparum, P. berghei, 
E. coli, D. radiodurans, using clustalW in the predicted domain linker regions; the 
consensus sequence characterizes identical residues as ‘*’, strongly similar residues as ‘:’ 
and weakly similar residues as ‘.’.  
 
The C and N-terminii do not contribute much toward ligand binding;
11
 hence, 
some residues in these regions were truncated while building the model (Figure 19). The 
model generated for PvDXS has residues starting from 375 and ending at 1011. Since no 
templates were available to model the starting sequence (residues ranging from 1-374), 
the model starts at residue 375. If the templates had gaps of more than 20 amino acid 
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residues, the gaps were retained in the model.  Substrates thiamine pyrophosphate (TPP) 
and the divalent metal ion (Mg
2+
) were retained from the X-ray crystal structure of D. 
radiodurans, while generating the model. 
The initial model was minimized to produce a better model for docking studies. 
The structure was minimized using Macromodel; limited memory Broyden–Fletcher–
Goldfarb–Shanno algorithm15 with OPLS_2005 forcefield.16 Macromodel minimization 
was performed for 500 iterations and a gradient convergence threshold of 0.1 Å.  
Homology models of P. knowlesi, P. falciparum and P. berghei  DXS (Figure 17) 
were also developed using similar protocol as described above. The sequences of P. 
knowlesi, P. falciparum and P. berghei DXS were obtained from NCBI. P. knolwesi has 
1122 residues, P. falciparum has 1205 and P. berghei has 843 residues respectively. They 
were aligned with the sequences of E. coli and D. radiodurans as described earlier. The 
sequence of P. knowlesi has high homology to P. vivax than P. falciparum or P. berghei 
and P. falciparum has high homology to P. berghei. The models of P. knowlesi, P. 
falciparum and P. berghei were built using the aligned templates and TPP, Mg
2+ 
retained 
from the D. radiodurans crystal structure. The initial model obtained was minimized 
using Macromodel; limited memory Broyden–Fletcher–Goldfarb–Shanno algorithm15 
was used for minimization with the OPLS_2005 forcefield.
16
 Macromodel minimization 
was performed for 500 iterations and an energy gradient convergence threshold of 0.1 
kcal/Å.   
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Figure 17.  Homology models of Plasmodium DXS; 17a. Homology model of PvDXS; 
17b. Homology model of PkDXS; 17c. Homology model of PbDXS; 17d. Homology 
model of PfDXS. 
 
As the alignment score suggests (Table 4), P. vivax has a high homology to P. 
knowlesi and P. falciparum has high homology to P. berghei. As seen from the alignment 
file (Figure 16), the sequences of D. radiodurans and E. coli align with the plasmodium 
species starting from residue 138 in P. berghei, 406 in P. falciparum, 343 in P. knowlesi 
and 347 in P. vivax. Since there are no templates available to model the starting residues, 
the model for each of the plasmodium species starts from where the sequence of D. 
radiodurans or E. coli begins.  
Active sites of the homology models of DXS generated were compared with the 
crystal structures of D. radiodurans and E. coli. It was found that the active-sites of the 
models generated were quite similar to the templates used. A comparison of the residues 
17a 17b 
 
17c 
 
17d 
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in the active sites is tabulated in Table 5. It is evident from the table that the active-sites 
share a higher degree of identity, with similar residues present in the region. 
Table 5. Comparison of residues in the active-sites of DXS (homology models and 
templates) 
 
Position D. radiodurans E .coli P.  vivax P. knowlesi P. falciparum P. berghei 
1 54:SER 52:SER 401:ALA 397:ALA 461:SER 182:PRO 
2 80:VAL 78:VAL 469:ALA 423:ILE 487:ILE 208:ILE 
3 82:HID 80:HID 471:HIS 425:HIS 489:HIS 210:HIS 
4 83:GLN 81:GLN 472:SER 426:GLN 490:GLN 211:GLN 
5 123:GLY 121:GLY 530:ARG 466:GLY 530:GLY 251:GLY 
6 124:HID 122:HID 531:GLY 467:HIS 531:HIS 252:HIS 
7 125:ALA 123:SER 532:GLY 468:SER 532:SER 253:SER 
8 153:GLY 151:GLY 558:GLY 561:GLY 572:GLU 302:GLY 
9 154:ASP 152:ASP 559:ASP 562:ASP 573:ARG 303:ASP 
10 155:GLY 153:GLY 560:GLY 563:GLY 574:ILE 304:GLY 
11 156:SER 154:ALA 561:GLY 564:GLY 575:PHE 305:GLY 
12 181:ASN 179:ASN 586:ASN 589:ASN 655:ASN 330:ASN 
13 183:ASN 181:ASN 588:ASN 591:ASN 657:ASN 332:ASN 
14 185:MET 182:GLU 591:VAL 594:VAL 661:SER 333:ARG 
15 186:SER 153:GLY 592:SER 595:SER 661:SER 304:GLY 
16 187:ILE XXX:XXX 593:LEU 596:LEU 662:LEU XXX:XXX 
17 289:LYS 284:LYS 681:LYS 702:LYS 751:LYS 426:LYS 
18 304:HID 288:TYR 696:HIS 717:ASP 773:ILE 430:PHE 
19 347:PRO 344:PRO 778:PRO 779:PRO 853:PRO 516:PRO 
20 348:ALA 345:ALA 779:ALA 780:ALA 854:ALA 517:ALA 
21 349:MET 346:MSE 780:MET 781:MET 855:MET 518:MET 
22 371:ILE 368:ILE 802:ILE 803:ILE 877:ILE 308:GLY 
23 373:GLU 370:GLU 804:GLU 805:GLU 879:GLU 541:GLU 
24 398:PHE 395:PHE 830:PHE 831:PHE 905:PHE 567:PHE 
25 401:ARG 398:ARG 833:ARG 834:ARG 908:ARG 570:ARG 
26 434:HID 431:HID 866:HIS 867:HIS 941:HIS 603:HIS 
Residues not having similar residues are shown in red 
The minimized structures were assessed for overall quality using Ramachandran 
plots. This plot checks the stereo chemical quality of a given protein structure by 
verifying the accuracy of parameters like bond angles, bond lengths, torsion angles and 
correctness of amino acid chirality. Using these criteria, the PvDXS model compares well 
with the available X-ray crystal structure of DrDXS and EcDXS.  
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 The Ramachandran plots of the homology models of PvDXS, PkDXS, PfDXS and 
PbDXS is shown in Figure 18. The plot clearly shows that the vast majority of the  
residues are in a phi-psi distribution consistent with right handed α-helices. The 
remaining residues that fall into the random or beta configuration geometries are small 
segments and are primarily present in the loop regions of the protein.  
A Ramachandran plot was generated from the PDBsum server. The homology 
model of PvDXS had 80.5% of total residues that lie in the favorable regions, while the 
disallowed regions had about 1.4% of the residues.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Ramachandran plots of Plasmodium DXS; 18a. PvDXS model; 18b. PkDXS 
model; 18c. PbDXS model; 18d. PfDXS model. 
 
4A 
18b 18a 
18c 18d 
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Figure 18 continued 
 
Plot 
Statistics 
PvDXS PkDXS PfDXS PbDXS DrDXS EcDXS 
Residues in 
most favored 
regions 
[A,B,L] 
446 80.5% 463 78.3% 486 71.1% 450 81% 1592  84.9%  1580 91.40% 
Residues in 
additional 
allowed 
regions 
[a,b,l,p] 
84 15.2% 99 16.8% 156 22.8% 78 14.2% 247  13.2%  132 7.60% 
Residues in 
generously 
allowed 
regions 
[~a,~b,~l,~p] 
16 2.9% 18 3.0% 23 3.4% 13 2.4% 19  1.0%  6 0.30% 
Residues in 
disallowed 
regions 
8 1.4% 11 1.9% 19 2.8% 9 1.6% 17  0.9%  11 0.60% 
 
Figure 18e. Statistics from Ramachandran plots of homology models and X-ray crystal 
structures of DXS 
 
 As DXS is an important enzyme for the biosynthesis of isoprenoids, pyridoxol 
and thiamine, targeting DXS in many organisms will prove important to find inhibitors 
for many infectious diseases. Diseases caused by B. anthracis, B. subtilis, K. 
pneumoniae, M. bovis, M. tuberculosis, V. cholerae, and T. pallidum occupy the top spots 
on the infectious diseases category list by the WHO.
28
 Homology models for DXS in 
other organisms were generated since crystal structures are not available. Homology 
models of B. anthracis, B. subtilis, K. pneumoniae, M. bovis, M. tuberculosis, V. 
cholerae, and T. pallidum were generated and validated using PROCHECK. 
Domain swapping 
Domain swapping is formed by swapping of the monomer subunits in a protein to 
form an intertwined oligomer. There are many proteins reported to domain swap, the best 
known example being Diptheria Toxin,
17
 which has been isolated in both monomeric and 
dimeric forms. ‘Hinge’ region is defined as the linker loop that connects the domain. In 
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the domain swapped dimer, the subunits of each monomer change partners, retaining 
similar interactions as the closed monomer. The ‘closed’ monomer refers to the protein in 
the monomeric state; the closed monomer has buried hydrophobic patches, which would 
become exposed in the open form (Figure 19). During swapping, the free energy of 
interaction between the monomeric subunits should compensate for the loss of entropy of 
the immobilized monomers.
18
 The domain swapped dimer has two C-interface regions 
between the two different subunits. C-interface refers to the ‘C’ shaped interface between 
the two domains of the monomer. Stability of the domain swapped dimer depends on the 
free energy release upon dimer formation; if the free energy release upon dimerization is 
much higher than the individual monomers, then the domain swapped dimer will have a 
longer half-life since the energy barrier is high for the interconversion.
18
  
Domain swapping is reported to occur in a vast variety of proteins. However, the 
length of the swapped regions differs vastly between each of them, varying from 15 
residues length in BS-RNAse to 150 residue globular domain in Diptheria toxin.
17
 
Domain swapping occurs for modulating activity or as an evolutionary process to 
form oligomers from monomers. Mechanism of oligomer evolution due to domain 
swapping is difficult to understand in proteins that dimerize during folding. However, 
certain proteins can undergo domain swapping upon denaturation of the monomers and 
again subjecting to renaturation conditions, particularly at high protein concentration.
18-20
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Figure 19. Domain swapping in proteins 
In the D. radiodurans crystal structure, residues 199-249 are missing indicating 
that there might be a domain swapping occurring at residue 198, by linking residue 198 
of domain I with residue 248 of domain II. If such is the case, then the structure of D. 
radiodurans would be similar to transketolase (TK) E. coli, where domain I would be 
above domain II and domain III of the other monomer and the active-site would lie in the 
dimer interface region.
21
 Similar to the crystal structure of D. radiodurans, the crystal 
structure of E. coli also has missing residues in the same region and is also implicated to 
domain swap in this region. If domain swapping occurs in P. vivax, the structure would 
resemble the structure of TK, with the active-site present at the dimer interface. It is 
hence important to predict whether P. vivax is domain swapped. 
In order to derive information about probable domain swapping in PvDXS, we 
analyzed the sequence for hinge regions, where swapping could occur. We studied the 
sequence derived structure entropy for PvDXS. The sequence derived structure entropy 
(SDSE) values for the protein sequences were calculated previously using tripeptides and 
tetrapeptides from different non-redundant databases as the standard.
22
 The disordered 
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regions based on loops/coils
23
 in the secondary structure were: residues 1-250, residues 
585-601 and around residue 727 (Figure 20). Disorder probability
24
 on the protein 
sequence for PvDXS indicated high degree of disorder in the residues 1-250, suggesting 
that this part of the protein could be the signal/transit peptide and residues 1-23 were 
detected to be the signal peptide.
25
  
 
Figure 20. Disorder probability of PvDXS, derived from sequence 
Domains are usually predicted through loop-length dependent support vector 
machine (based on machine learning algorithms).
26,27
 Based on the above studies, PvDXS 
is predicted to have three domains, Domain I ranging from residue 250-582, 583-609 is 
the domain swapped region, domain II ranging from residue 609-724 and domain III 
ranging from residue 725-1111. We predict that domain swapping could occur in PvDXS 
between residues 583-609, which form the linker between domain I and domain II.  
We used the SDSE
22
 tool to generate the entropy based on sequence. This was 
done to ensure the regions of swap were determined correctly. To confirm the region of 
domain swap, the proline, histidine and isoleucine residues that lie in the disordered 
region between domain I and II were mutated to alanine and entropy change was 
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calculated; the results of which are shown in supplementary information. There was a 
huge gain in entropy for the isoleucine residues mutated to alanine, in the predicted swap 
region (Table 6). The proline residues present in the hinge region showed a loss of 
entropy when mutated to alanine, which also confirms that they provide the rigidity 
associated with domain swap. Based on the results, it is evident that the domain swap 
occurs in the region 583-609. 
Table 6. Entropy difference on alanine mutation in the predicted domain linker 
region of PvDXS 
 
Residue Entropy Mutant Entropy S 
H499 0.87006 H499A 1.28247 0.412407 
P500 1.39877 P500A 1.47198 0.073211 
H510 1.38436 H510A 1.34371 -0.04065 
P511 1.52913 P511A 1.40586 -0.12326 
H527 1.38635 H527A 1.45683 0.070476 
P528 1.4274 P528A 1.43547 0.008071 
P540 1.44851 P540A 1.39533 -0.05318 
I583 1.09052 I583A 1.1942 0.103685 
I584 1.12959 I584A 1.29053 0.16094 
P594 1.27088 P594A 1.45006 0.179181 
P598 1.42308 P598A 1.39244 -0.03064 
P605 1.28438 P605A 1.26844 -0.01594 
I606 1.29282 I606A 1.4603 0.167478 
I609 1.35446 I609A 1.47025 0.115785 
H612 1.55882 H612A 1.40138 -0.15745 
H614 1.39783 H614A 1.24602 -0.15181 
 
Similarly, for P. knowlesi, the domain swap is predicted to occur between residues 
586-612. For P. falciparum and P. berghei, the domain swap regions predicted are 
residues 653-678 and 327-353 respectively. 
Residue H510 is specific to PvDXS and is absent in all other plasmodium species, 
indicating that this residue might play an important role in the swapping mechanism. The 
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entropy change for H510A is very high, which suggests that this residue might be tightly 
bound to the substrate or held together by hydrogen bonding and or Van Der Waals forces 
and the proline residue, P511 adjacent to H510 could assist in the swapping mechanism.  
Salt bridges might reveal important information in regard to domain swapping.
19
 A salt 
bridge is formed between ASP587-HIS676 in PvDXS, indicating that in the domain 
swapped conformation; this salt bridge could still be retained such that a salt bridge is 
formed between ASP587 of one monomer and HIS676 of the other monomer. Similar 
observations are seen in P. knowlesi, P. berghei and P. falciparum.  
 To determine the structure of domain swapped PvDXS, comparative modeling 
was performed using E. coli transketolase (PDB: 2R8O) as an additional template (along 
with E. coli DXS and D. radiodurans DXS), which had only 9% sequence identity with 
the sequence of PvDXS (Figure 21a). The model was validated by generating 
Ramachandran plots. 
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Figure 21. Model of PvDXS using E.coli transletolase as one of the templates; 21a. 
Homology model of PvDXS based on E. coli transketolase template; the regions shown 
in pink are the closed gaps. 
 
Figure 21b. Active site in the initial model of PvDXS using E.coli transketolase as one of 
the templates and the Ramachandran plot of the initial model; TPP carbons are colored 
brown. 
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Figure 21 continued 
 
Figure 21c. Active site in the final model of PvDXS using E.coli transketolase as one of 
the templates and the Ramachandran plot of the final model; TPP carbons are colored 
cyan. 
 
 However, as seen in Figure 21b, the phenyl ring of TPP is seen to occupy the 
region close to Pro511 and His510. The side chains of the residues were slightly shifted 
using the transform tool of Maestro 8.5.2, such that the residues no longer overlap with 
TPP. The model was treated for bond orders, bond angles; protonation states and energy 
minimized using Impact in the Protein Preparation step. Later the prepared protein model 
was energy minimized employing MacroModel, using the LBFGS algorithm. The refined 
structure was validated using Procheck. The refined structure had a score of 77.8% 
(Figure 22c) for the residues in the most favorable regions, 19.2% for residues in the 
additionally allowed regions, 1.7% for residues in generously allowed regions and 1.2% 
for residues in the disallowed regions. In comparison to the previous Ramachandran plot, 
the residues in the most favorable regions have changed from 81.6% (Figure 21b and 
21c) to 77.8% in the refined model, but the residues in disallowed regions have changed 
from 2.2% (13 residues) to 1.2% (7 residues). Moreover, the residues in the disallowed 
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regions were manually inspected for their vicinity to the active-site. It was found that 
these residues lie in the regions not occupied by the active-site. The above results suggest 
that the refined model may be a better one compared to the previous models to perform 
docking studies. 
Mutation studies on D .radiodurans DXS 
 Mutation studies was perfomed in D. radiodurans DXS to understand better, the 
underlying mechanism of catalysis and the residues involved in TPP and/or G3P binding. 
Some mutants and their effect on catalysis have previously been reported for DXS.
21
 We 
performed computational alanine scanning studies on the residues present in 5 Å shell of 
TPP and Mg
2+
 cation (Figure 22). Residues were individually mutated to alanine and the 
difference in TPP binding via docking was observed for each of the residues.  
Docking was performed using TPP as the ligand for the mutants N183A, H82A, 
N181A, Y395F and Y395A. For H434A, D430A and R423A, TPP-G3P adduct was used 
as the ligand to calculate the XP scores and the RMSD. The mutant was identified to be 
important for activity if there was a significant difference in docking scores (XP) and/or a 
difference in RMSD of TPP/TPP-G3P with reference to WT. Mutants important for 
catalysis, thus identified, were synthesized in collaboration with Dr. Merkler’s research 
laboratory and activity studies were performed.
29
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Figure 22. Residues in 5 Å shell of TPP; Mg
2+
 is shown in pink and is hydrogen bonded 
to TPP, Asp154, and Asn183. 
 
 Table 7 shows the list of mutants identified computationally and their effect on 
catalysis. The kinetic parameters were measured by varying the initial concentration of 
G3P. For reference, the XP scores of TPP and TPP-G3P adduct are given in table 7. 
Comparing the XP scores and RMSD values with TPP for N181A, N183A, H82A, Y395F 
and Y395A and TPP-G3P adduct for H434A, D430A and R423A mutants, it can be 
inferred that a greater RMSD difference showed a significant change in Km values. For 
RMSD value of 0.95 and lower, there was no change in the Km values. Thus, 
computational prediction of catalytically important mutants also gave a good correlation 
with experimental values. 
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Table 7. Mutants with the RMSD and Km values (compared to WT) 
Mutant XP Score  RMSD  Km (mM) Function 
TPP-G3P  -19.218 0 -- -- 
R423A  -16.517 0.9574 0.05±0.09 G3P binding  
H434A  -16.265 1.2314 12.3±3.2 G3P binding 
D430A  -15.128 1.9833 0.12±0.01 G3P binding 
TPP  -15.214 0 0.05±0.01 --  
N183A  -13.99 0.3642 0 TPP binding  
H82A  -14.877 0.4958 0.03±0.01 Proton Transfer  
N181A  -14.689 0.6959 0.03±0.01 TPP binding  
Y392F  -13.4433 0.9604 0.59±0.04 TPP binding  
Y392A  -13.6584 1.9801 0.67±0.05 TPP binding  
 
Conclusion 
In conclusion, homology models were developed for DXR from P. falciparum, Y. 
pestis towards the goal of developing new inhibitors for other infectious diseases as well, 
as reported in the WHO infectious diseases factsheet. We have also virtually screened the 
NCI diversity set II compounds to establish ‘hits’ for the target enzymes.  As DXR is the 
first committed enzyme in the NMP pathway for the biosynthesis of isoprenoids, 
targeting DXR in many organisms will prove important to find inhibitors for many 
infectious diseases. 
We have also generated homology models for various species of DXS and DXR. 
For P. vivax DXS, we have generated two homology models, one based on domain 
swapped architecture and the other , when the protein is not domain swapped. All the 
homology models were sufficiently validated to be used in structure-based drug design. 
Compounds from the NCI Diversity Set, GSK-MMV compound library and St-Jude’s 
children’s research Center compound libraries have been docked and potential inhibitors 
identified for each of the DXS and DXR species modeled. We have also computationally 
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identified mutants important for TPP and G3P binding, which were confirmed 
experimentally. 
Future Direction 
The compounds that were found ‘hits’ based on virtual screening could be tested 
on the DXS-DXR coupled assay developed in-house in Dr. Merkler’s lab. The 
compounds that prove to inhibit in the cellular assay could be re-synthesized and tested 
for activity. In addition, the ‘malaria box’ compounds have been ordered and the 
compounds could be tested in the DXS-DXR coupled assay to find a potential inhibitor 
for the enzyme. 
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Chapter 5 
Validation of dimer interface as a binding site in E. coli FabH 
Introduction 
The dimerization interface of FabH in E. coli is approximately 3200 Å
2 
as 
revealed by its crystal structure (PDB ID: 1HN9)
1
 (Figure 23). This structure was chosen 
because of its high resolution compared to the earlier ones. This structure does not have 
any ligand bound (except for phosphate which is distal to the active site and does not 
appear to play a catalytic role), which is essential to understand the dynamics of the 
unliganded system. However, this orthogonal space group structure is similar to the 
reported structures with ligands bound.
18,19
  
 
Figure 23. Crystal structure of E. coli FabH (ribbon representation); Residue in the dimer 
interface region, Phe87 is represented as ball and stick and colored blue. 
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SiteMap analysis 
The important residues in the dimer interface are oriented towards the surface of 
the monomer in the interface region.
2
 To probe the dimer interface as a probable binding 
region, SiteMap
3
 analysis was performed on the monomer and dimer. This analysis 
would also help identify the hot spots present in the dimer interface region.
4
 As discussed 
earlier, the dimer interface behaves like a protein-protein interface. To validate the 
SiteMap analysis performed on FabH, we performed SiteMap analysis on proteins that 
are known to be involved in protein-protein interactions (PPI). In the current 
investigation, the proteins chosen were Interleukin-1 receptor (IL-1),
5, 6
 MDM2,
7, 8
 and 
Bcl-xL.
9, 10
 All of these proteins have previously been reported to be involved in PPI and 
had either a peptide or a non-peptidic ligand bound to the active site (Figure 24).
11
 The 
analysis was performed to determine whether SiteMap could identify the binding sites 
occupied by the native small molecule or peptide in the respective proteins. In all the 
cases, the SiteMap tool identified the binding site within the top two site rankings (Table 
8). 
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24a 24b 
24c 24d 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. SiteMap analyses on proteins known for PPI; 24a. Binding site of IL-1 
receptor
6
 analyzed by SiteMap; the native peptide is colored magenta; 24b: Binding site 
of the MDM2
8
 analyzed by SiteMap; the native peptide is colored magenta; 24c and 24d: 
Top two binding sites identified by SiteMap on the protein Bcl-xL
10
; the native ligand 
(ABT737) is colored magenta; The binding sites are represented as hydrophobic, H-bond 
donor and H-bond acceptor maps (blue: hydrogen-bond donor; red: hydrogen bond 
acceptor; yellow: hydrophobic). 
 
SiteMap is a tool that identifies putative binding sites by analyzing a number of 
parameters that contribute to tight binding of the ligand with the receptor.
12
 “Site points” 
are identified to define a binding region and linked together depending on the closeness 
of the site points to the protein surface and solvent accessibility. The SiteMap program 
returns a number of binding site parameters: site score, size, exposure score, enclosure, 
contact, hydrophobic/hydrophilic character, donor/acceptor character.  The “size” of a 
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binding site is approximated by the number of site points contained within a putative site. 
Based on the analysis by Halgren
13
 (described later in the paragraph), the average number 
of site points for submicromolar sites is 132. Lower exposure scores are better, 0.52 
being the average for submicromolar sites; higher enclosure scores are good with an 
average of 0.76 for submicromolar sites. For contact, the average score is 1 as it is for the 
hydrophobic/hydrophilic character. For the donor/acceptor character and site score, the 
average for the submicromolar sites is 0.76 and 1.01 respectively.  Another parameter: 
Dscore or druggability score gives a rough estimate of whether the site is druggable. 
These scores were derived by Halgren,
13
 by executing the SiteMap program on a number 
of proteins that have inhibitors bound with potencies in the submicromolar range and 
performing statistical analyses to produce optimized scores.
13
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Table 8. SiteMap analysis on FabH (monomer and dimer) and other proteins involved in 
PPI; 
d
Dimer interface binding sites identified by SiteMap;
*
used in this study. 
Title 
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Interleukin 
Receptor-1 
1.05 427 1.03 1100.34 0.43 0.77 1 0.59 1.15 1 
MDM2 0.92 39 0.98 99.13 0.59 0.73 0.92 3.32 0.13 5.87 
Bcl-xL-Site1 0.94 48 0.99 128.63 0.56 0.74 0.93 2.78 0.34 11 
Bcl-xL-Site2 0.71 43 0.73 114.91 0.75 0.51 0.65 0.77 0.6 2.75 
Monomer-Site1* 1.1 83 1 112.5 0.35 0.94 1.3 1.06 1.31 0.13 
Monomer-Site2§,* 1.01 103 1.07 288.81 0.69 0.64 0.81 0.84 0.77 0.98 
Dimer-Site1 1.1 82 1 112.16 0.35 0.95 1.29 1.04 1.28 0.13 
Dimer-Site2 1.04 104 1.04 210.95 0.48 0.76 1.01 0.79 1.07 0.24 
Dimer-Site3§ 1.07 267 1.02 485.69 0.49 0.8 1.04 0.58 1.24 0.83 
Dimer-Site4§ 0.86 63 0.91 204.43 0.77 0.59 0.68 0.71 0.58 1.11 
Dimer-Site5§,* 0.84 72 0.84 251.76 0.75 0.62 0.71 0.25 1.01 1.12 
 
a: used to identify and compare binding sites, a score of 0.8 or higher is generally considered a binding site; 
b: number of site points for the given binding site, a size of 132 or higher is optimal for submicromolar 
sites; c: criterion to decide whether or not the site is druggable, a score greater than 0.98 is considered 
“druggable”; d,e,f: refers to the openness of the binding site to the solvent, lower exposure scores and 
higher enclosure scores are considered better; g: a measure of vdW non bonded interactions of the site 
points with the receptor, average score for submicromolar sites being 1.0; h,i: refers to the hydrophobic and 
hydrophilic properties of the binding site respectively, average scores are 1.0 for submicromolar sites; j: 
refers to the ability of the ligand to donate or accept hydrogen bonds, average score for submicromolar sites 
is 0.76. 
From Figure 24 and Table 8, it is evident that SiteMap found the active site at 
ABT737 binding site (a known inhibitor for Bcl-xL) with a site score of 0.94 and Dscore 
of 0.99 for the protein Bcl-xL.
10
 The second binding site as identified by SiteMap also 
indicates the pocket occupied by the molecule ABT737. Bcl-xL has four hydrophobic 
pockets p1-p4 that are occupied by the residues of the molecule ABT737,
10
 out of which 
the pockets p1-p2 are placed close to each other and p3-p4 are placed close to each other 
with space between them. The pockets closer to each other were found as a single binding 
region in the SiteMap analysis. As seen in Figures 24c and 24d, SiteMap identified both 
the binding sites for Bcl-xL as described earlier. For MDM2,
8
 the site score was 0.92 and 
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Dscore was 0.98. For the Inter-Leukin-1 receptor,
6
 the site score at the active site was 
1.05. These scores were well within the ranges as described by Halgren.
13
 The 
aforementioned study was performed in order to calibrate the scores we obtained for 
FabH dimer interface binding site. 
SiteMap analysis performed on the monomeric and dimeric FabH is also tabulated 
in Table 1. SiteMap identified five different binding sites for the FabH dimer. According 
to Table 1, Dimer-Site1 and Dimer-Site2 were the biological active-sites within the 
individual monomers. Dimer-Site3 was found to have the largest area in the dimer 
interface region while Dimer-Site4 and Dimer-Site5 occupied shallow binding pockets in 
the dimer interface region. For monomeric FabH, SiteMap identified two probable 
binding sites; Monomer-Site1 was the biological active site while Monomer-Site2 was 
the dimer interface, which is used in this study (Figure 25). The dimer interface region 
was identified as a potential binding site in monomer and the dimer with a site score 
greater than 1. A Dscore of 1.02 for the dimer interface binding region implies that the 
site is “druggable” according to Halgren et. al.13 (where values greater or equal to 1 are 
favored). This binding region has lower exposure scores and higher enclosure score, 
which is optimal for a submicromolar binding site. The donor/acceptor character of the 
dimer interface binding sites in the monomer and dimer is also closer to the optimal 
value. These findings indicate that Monomer-Site2 is a hot spot binding region
4
 since the 
residues that comprise the binding region (Phe87 and its complementary residues from 
the other monomer; Thr190, Leu191, Pro192, Asn193) are important for the stability of 
the FabH dimer.
14
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Figure 25. Sitemap analyses on monomer and dimer FabH; analysis was performed on 
the crystal structure (PDB ID: 1HN9), protein represented as a cartoon; Binding sites are 
represented as a donor-acceptor hydrophobic map; Analyses are summarized in Table 1; 
25a: dimer-site1, 25b: dimer-site2, 25c: dimer-site3, 25d: dimer-site4, 25e: dimer-site5, 
25f: monomer-site1, 25g: monomer-site2.  
 
25a 25b 
25c 25d 
25e 25f 25g 
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An overview of the results from the SiteMap analysis is shown in Table 8. It can 
be seen that SiteMap identified the dimer interface as a potential binding site in both the 
monomer and the dimer with a site score greater than 1. The Dscore for the dimer 
interface binding region was found to be slightly higher than 1, which implies that the site 
is “druggable” according to Halgren et. al.13 This binding region has lower exposure 
scores and higher enclosure score, which is optimal for a submicromolar binding site. 
The donor/acceptor character of the dimer interface binding sites in the monomer and 
dimer is also closer to the optimal value.   
Findings from the SiteMap analyses reveal that dimer interface in FabH could be 
an interesting allosteric site of inhibition. This fact could be exploited in drug design, by 
creating an inhibitor that could lock FabH in its monomeric state and hence would render 
the protein significantly less active than when in the dimeric state as discussed earlier. In 
order to design inhibitors of this type, a detailed knowledge of the dimer interface 
structure is essential.  
Molecular dynamics 
To probe the conformational space accessible to this dimer interface in solution, a 
20 ns MD simulation of the FabH monomer was carried out. For comparison purposes, 
we carried out a 20 ns MD simulation on the FabH dimer.  
MD simulations were performed using the DESMOND module available from 
DE Shaw Research Group
15
 using the OPLS-2005 force field. The solvated protein was 
energy minimized using the DESMOND minimization algorithm, 2000 iterations and a 
energy gradient convergence threshold of 1 Kcal/mol/Å were employed. The minimized 
protein was relaxed before the actual simulation by a series of minimizations and short 
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MD simulations to relax the model system before the actual simulation is performed. 
There are six steps in the relaxation process; the first two steps are minimization steps, 
solute restrained and without restrains, steps three through six are short MD simulations 
of 12ps, 12ps, 24ps and 24ps each using the NPT ensemble at 10 K, 10K, 300 K and 300 
K respectively. Velocity resampling is done in steps three through five while step six 
does not include velocity resampling.  
The NPT ensemble and Nose-Hoover chain thermostat and Martyna-Tobias-Klein 
barostat were employed for the actual simulations and the RESPA integrator was used 
with a time step of 0.002 ps. A 9 Å cutoff was used for the Coulombic interactions, while 
the electrostatics was treated using the particle mesh Ewald method, with a tolerance of 
1e-9 Å. Hydrogen bonds were constrained using the ‘M_SHAKE’ algorithm of 
DESMOND. The coordinates were saved at intervals of 4.8 ps, referred to as ‘frames’ in 
this study. The monomer and dimer simulations were carried out for comparative 
purposes and were sampled over 20 ns, coordinates saved every 4.8 ps.  
Protein systems have to be stabilized in order to achieve predictable results form 
the MD run. Root mean square deviation (RMSD) is a good indicator of overall stability 
of the protein-solvent systems. RMSD of the Cα atoms were followed over the 20 ns time 
period. All the analyses were performed using the Simulation Event Analysis tool 
available in DESMOND.
15
 All frames are aligned with the starting structure prior to the 
calculations. RMSD was measured for the C  atoms using starting structure as the 
reference frame, according to the formula,  
RMSDt = 
N
nN 1
2
0n
 ) X- (X 
1
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where Xn refers to the coordinates of C  atom of a particular residue at time t and X0 
refers to the coordinates of C  atom of the same residue in the initial structure (Frame 0) 
at 0 ns, and N refers to the number of residues. Thus, RMSD at a given time t is the 
average deviation of the C  atoms of all residues at time t with respect to frame 0. RMSF 
was measured as the mean fluctuation of C  atoms of the individual residues over the 20 
ns simulation, according the formula,  
RMSFn = 
T
tT 1
2
t
)X-(X
1  
 
where Xt refers to the fluctuation of C  atom of a particular residue n at time t, X  refers 
to the mean fluctuation of the same residue over the entire simulation time. Thus, RMSF 
of a residue is the mean fluctuation of that residue over all the time frames. Radius of 
gyration was calculated according to the formula,  
Rt = 
N
n
n
YY
N 1
2
)(
1
  
where Yn refers to the distance of a particular residue from the centroid at time t and Y  
refers to the mean distance of all residues from the centroid for that time t, and N refers to 
the number of residues. 
In the dimer, the protein was found to be fairly stable during the entire simulation 
with a mean RMSD of 1.12 ± 0.08 Å, while the monomer converged between 10-12 ns 
and had a mean RMSD of 2.52 ± 0.44 Å (Figure 26). Radius of gyration is another 
indicator of protein stability. Radius of gyration for the monomer and dimer during the 20 
ns simulation time was followed, which indicated both the systems to be stable (Figure 
27).  
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Figure 26. RMSD for the monomer (blue) vs. Dimer (red) FabH. 
 
 
 
Figure 27. Radius of gyration measured for the monomer (blue) and the dimer (red). 
 
Root mean square fluctuation (RMSF) plot is a measure of the average fluctuation 
of the residues over time. RMSF over different time frames were plotted to determine the 
convergence of individual residues and analyze the fluctuations of dimer interface 
residues over the simulation time. The monomer was found to converge between 10 and 
12 ns (Figure 28a), while the fluctuations were minimal throughout the dimer simulation 
(Figure 28b). These results correlate well with the RMSD data (Figure 26). The residues 
that had large fluctuations were the ones in the dimer interface region or the residues 
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adjacent to the active-site. The fluctuations of residues in the dimer interface region in the 
monomer were almost twice as much as the dimer. These explain the large 
conformational changes undergone by the solvated monomers compared to the dimer.  
A RMSF difference plot was generated by plotting the difference in RMSF of the 
monomer and dimer. This was done to predict the regions that had significant change 
during the simulation. In the RMSF difference plot (Figure 28d), any fluctuation above 
the ± 0.5 Å region was considered significant. Residues that had large fluctuations were 
residues 31-38, 86-89, 129, 191-208, 224, 253-265. These regions were labeled 1 through 
6 in the RMSF plots and the loops corresponding to those numbers in the plot are shown 
in Figure 30e respectively. Peak 1 comprises residues 31-38 which lie in the entrance of 
the biological active-site and hence shows large motions. Peak 2 has the Phe87 residue 
which is solvent accessible in the monomer but is buried in a hydrophobic pocket in the  
dimer and hence shows large fluctuations in the monomer while being stable in the 
dimer. Peak 3 encompass residues 126 through 131, which are present at the dimer 
interface. Peak 5 comprise of residues 181-217, which form part of an α-helix and a large 
loop that extends over the dimer interface region. Peak 6, which is also absent in the 
dimer, comprises of residues 253 - 265 that are present closer to the catalytic triad; they 
show large fluctuations in the monomer thereby changing the active site architecture, 
while being stable in the dimer. Residue 224 is the only residue that has negative RMSF 
in the monomer compared to the dimer, which can be explained by its proximity to the 
catalytically important residue, Asn274. These results confirm our hypothesis, which 
states that the changes occurring in the dimer interface in turn creates huge active site 
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architectural change in the solvated monomers such that the solvated monomers would be 
unable to accommodate substrate or ligand at the biological active site.  
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Figure 28. RMSF plots of monomeric and dimeric FabH; 28a. RMSF over different time 
frames for FabH monomer; 28b. RMSF over different time frames for FabH dimer; 28c. 
RMSF of monomer and dimer over the 20 ns simulation (Red: Dimer, Blue: Monomer); 
28d. RMSF difference plot of monomer vs. dimer over the 20 ns simulation. 
 
 
 
Figure 28e. FabH dimer and the peak labels corresponding to the RMSF plots 
Figure 28 continued      
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Principal Component Analysis (PCA) 
PCA is an efficient analysis tool to reduce the number of variables and analyze 
specific motions. The major motions of the protein system are generally captured in the 
first few principal components. Covariance matrix of every 10
th
 step of the trajectory for 
the monomer and dimer systems was generated using the 
trajectory_covariance_matrix.py script of DESMOND; which generated a 1902*1902 
(3N*3N) matrix for the dimer and a 951*951 (3N*3N) matrix for the monomer 
respectively. PCA was performed on the covariance matrix using MATLAB 2010 
environment and the graphs were plotted in Excel.  
 The plots of the first two principal components (PC1 and PC2) of the monomer 
and dimer are shown here, while plots of principal components 3 through 5 (PC3, PC4 
and PC5) are shown in Appendix 3(pg 137).  The first 5 PC accounted for 78% of the 
motion in the monomer and 58% in the dimer respectively. As observed in the RMSF 
plot of the monomer, PC1 and PC2 both show fluctuations in the regions containing 
residues 78-111 (peak 2 in in Figure 28a) and 244-267 (peak 6 in Figure 28a) (Figure 29a 
and 29b). In the dimer, PC1 show fluctuations in the regions containing residues 32-50, 
66-89, 117-127, 134-148 and 240-246 (Figure 29c); PC2 shows fluctuations in the 
regions containing residues 59-90, 126-160, 190-219, 235-245 and 271-310 (Figure 29d). 
Comparing the scale of monomer vs. the dimer PC plots, fluctuations in the dimer are 
very minimal and are around the same value for all the peaks, indicating that the 
fluctuations are not as significant as in the monomer. These plots correlate well with the 
RMSF plots and again confirm our hypothesis that the changes occurring in dimer 
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interface would in turn create huge conformational changes in the biological active site 
architecture in the solvated monomers. 
  
  
 
Figure 29. PCA plots; 29a. PC1 plot of monomer; 29b. PC2 plot of monomer; 29c. PC1 
plot of dimer; 29d. PC2 plot of dimer. 
  
Biological active site   
In FabH, the active site is composed of a catalytic triad formed by residues, 
Cys112, His244 and Asn274 (Figure 30a).
16
 Residue Cys112 is involved in acetyl 
transfer while His244 and Asn274 play an active role in decarboxylation.
1
 Residues 
His244 and Asn274 are present close to Cys112 in the long active site tunnel, such that 
the distance between the CαH244 – CαN274  atoms is ~ 8 Å. Cysteine 112  lies on the bottom 
of the active-site tunnel, the entrance of which is flanked by residues Trp32 and Arg151, 
as discussed earlier.
17
 The per-residue RMSD plot over the 20 ns simulation time shows 
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that the catalytic residue Cys112 fluctuates with a maximum RMSD of 24.6 ± 4.8 Å in 
the monomer (Figure 30b). In the dimer, this catalytic residue shows greater fluctuations 
with a maximum observed RMSD of 35.2 ± 7.5 Å for the 20ns simulation. This indicates 
that the catalytic residue fluctuates in order to accommodate the binding of the substrate, 
and one would have to include induced fit effects when docking inhibitors in the active 
site.
18
 There are numerous examples of catalytic residue fluctuations to accommodate 
substrate binding. For example, penicillopepsin protein (PDB ID: 1BXO) has residue 
Tyr75 at the tip of a -hairpin loop that forms the catalytic pocket, which shows large 
fluctuations to accommodate the docking of inhibitors.
18
 Interestingly, our analysis shows 
that the fluctuations for Cys112 are minimal in the monomer as compared to the dimer.  
In the monomer the active-site conformation is changed and presumably can no longer 
accommodate Acetyl-CoA or substrate.  
The distances between the Cα atoms of His244, Cys112 and Asn274, Cys112 
were calculated during the 20 ns simulation time to understand the dynamics of the 
catalytic residues. In the dimer, the distance between Cys112 and the other two catalytic 
residues remain between 9 – 10 Å. In the monomer, a significant difference could be 
observed for both the distances. The distance between Cys112 and His244 remains 
around 9 Å for the first 3.5 ns, but is drastically lowered by ~ 1.5 Å for the rest of the 
simulation (Figure 30c). The distance between Cys112 and Asn274 stays at ~ 9 Å for the 
first 3.5 ns but increases quickly by ~ 1.5 Å for the remaining simulation time (Figure 
30d). This shows that the biological active site has undergone huge conformational 
change; Cys112 and His244 came closer to each other while Cys112 and Asn274 drifted 
away changing the architecture of the tunnel-like active site. 
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The mechanism of FabH proposed by Qiu et al.
18
 suggests a proton transfer 
between the thiolate hydrogen of Cys112 and N  nitrogen of His244, which generates the 
thiolate anion that attacks the carbonyl carbon of acetyl CoA (Figure 9e) and a final 
proton transfer between Nα nitrogen of H244 that is protonated, and thiolate anion of 
Cys112 after condensation. If such was the case, then the two atoms to be involved in 
proton transfer would be expected to be at an optimum distance to aid the transfer. The 
distance between these atoms in the crystal structure is 3.682 Å. We followed the 
distance between the thiolate hydrogen in Cys112 (-SH) and the Nα nitrogen in His244 
(N) (Figure 9f) to check if it changes in the solvated monomers, since the active site has 
undergone huge conformational changes. This distance starts around 3 Å in the monomer 
and remains around that value for the first 3.5 ns before increasing by a stark 5 Å for the 
rest of the simulation, while the distance stays around 4 Å for the dimer. A distance of 4 
Å could be argued to be an optimal distance between the two atoms to be involved in 
proton transfer as is the case with the dimer. In the monomer, this value shifts to around 8 
Å suggesting that the side chains of these two residues swing away from each other due 
to a conformational change of the active site. The solvated monomers undergo a huge 
conformational change in the active site caused by the increased proximity of the Cα 
atoms of Cys112 and His244, which in turn moves the side chains of these two residues 
away from each other, thereby increasing the distance between the atoms involved in 
proton transfer. This suggests that in the monomer, if catalysis does occur, it does so at a 
much slower pace than the dimer. 
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Figure 30 continued 
 
30g 
 
Figure 30. Distance plots for the catalytic triad; 30a. Active site tunnel of FabH 
(represented as ribbon) showing the catalytic triad, Cys112, His244 and Asn274 
represented as CPK and colored coded according to elements present; 30b. Per-residue 
RMSD plot for Cys112 for 20 ns simulation; 30c. Distance plot for the Cα atoms between 
Cys112 and His244; 30d. Distance plot for the Cα atoms between Cys112 and Asn274; 
30e. Proposed mechanism of proton transfer between His244 and Cys112 as proposed by 
Qiu et.al.
1
;30f. Distance plot between Cys112-SH proton and sp2-hybridized nitrogen of 
His244; 30g. Active site tunnel of FabH (represented as ribbon) in the average trajectory 
structure of the monomer (left) and dimer (right) showing the catalytic triad, Cys112, 
His244 and Asn274 represented as CPK and colored coded according to elements 
present; Distances between the C  atoms of Cys112 and His244, Cys112 and Arg274 and 
the distance between thiolate hydrogen of Cys112 and N  nitrogen of His244 are shown. 
 
The biological active site of FabH occupies a long cylindrical tunnel as explained 
earlier. The side chains of residues Trp32 and Arg151 are reported to open and close 
upon binding the substrate.
17
 The distance between these two residues is an important 
factor to be considered, since it determines the ligand binding affinity within the 
biological active site. The distance between the Cα atoms of these key residues was 
investigated over the course of the simulation in the monomer and dimer. The distance 
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between the Cα atoms of these two residues in the monomer is found to fluctuate by a 
greater degree than the dimer (Figure 31). Moreover, the average distance in the 
monomer is 2.25 Å greater than for the dimer, which explains tighter substrate binding in 
dimer. The initial distance between the two residues is around 2 Å in the closed form, 
which could be a tight binding conformation. In the open form, the distance between the 
residues increases, making the active site more accessible but not necessarily tight 
binding.                                                                                                   
 
Figure 31. Distance between the residues Trp32 and Arg151 in the monomer (blue) and 
the dimer (red). 
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Figure 32. Hydrophobic pocket formed by residue Phe87 and complementary residues 
from the other monomer; molecular surfaces generated for Phe1087 (left) and 
complementary residues (right) separately in two pictures for clarity. 
  
In the next step, we wanted to analyze the dynamics at the dimer interface, 
especially the hydrophobic pocket formed by Phe87 as a hot spot in the dimer interface 
region (Figure 32). Torsion angles provide good indication of the secondary structure of 
proteins; large fluctuations usually indicate a huge conformational change. Residues 
(Ala83, Thr84, Ala86, Phe87, Asp107, Ala109, Tyr 125, Ala183, Ser184, Thr190, 
Leu191, Pro192, Asn193, and Ile203) were analyzed for torsion-angle fluctuations during 
the 20 ns simulation in the monomer and dimer. The phi and psi angles were measured 
using simulation event analysis of DESMOND and the dials plots were recorded using 
“R” language and environment for statistical computing19 with an in-house script.20 In the 
monomer, residues (Ala83, Thr84, Ala86, Als109, Ala183, Ser184, Thr190, Leu191, and 
Asn193) show large fluctuations from the initial value (shown as a green dot in Figure 
34). In Figure 34, Ramachandran plots were recorded as scatter plots in Excel. In the 
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monomer, the side-chains of these residues seem to be highly flexible during the MD 
simulation, which has a dramatic effect on the hydrophobic pocket in which residue 
Phe87 is embedded. Residues Asp107 and Tyr125 that lie in the ß-sheet and left handed 
α-helix regions, show localized fluctuations compared to the residues in a loop (Figure 
34).  
The deviation for the two angles of the loop residues from the initial value 
indicates that the starting conformations of these residues are not representative for the 
monomeric state in aqueous solution (Figure 34). Residues Tyr125, Ala182, Asn193 and 
Ile203 greatly deviate from the initial orientation, the dihedral angles shifting almost 60  
- 120  degrees from the initial position (Figure 33). 
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Figure 33. Dialsplots of the  and  angles of the residues in the interface region for the 
monomer in E. coli FabH over the 20 ns MD simulation. The center point corresponds to 
0 ns and the edge corresponds to 20 ns. Each residue has two plots, first plot represents 
the  angle while the second plot represents  angle. 
 
Monomer Dimer 
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Figure 34. Scatter plots of the  and angles of the residues in the interface region for 
the monomer in E. coli FabH over the 20 ns MD simulation; the starting structure 
dihedrals are represented by a green dot. The angles are plotted on a Ramachandran plot 
background to clearly identify the beta sheet and alpha helical regions. 
 
 To study the conformational changes in the dimer interface region of the 
monomer, trajectory clustering was performed using DESMOND.
15
 Trajectory clustering 
was performed using the ‘single’ linkage method, based on the backbone RMSD in 
DESMOND. The analysis identified the top ten clusters, the representative members 
being: frames 160, 580, 820, 1260, 1700, 2020, 2330, 2640, 3420, 4140 corresponding to 
simulations times of 0.77, 2.78, 3.94, 6.05, 8.16, 9.70, 11.18, 13.25, 16.42 and 19.87 ns, 
respectively. Conformational changes occurring in the biological active site is shown in 
Figure 37. Each of the snapshots is superimposed with Frame 0 for easy visualization of 
Monomer Dimer Monomer Dimer 
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conformational changes in the residues shown. Conformational changes occurring in 
residues complementary to Phe87 pocket have been illustrated in Appendix 3 (Pg. 134). 
SiteMap analysis was performed on the representative members of each cluster to 
identify the binding regions in each; they were compared to the SiteMap results from 
Frame 0 (Frame 0 corresponds to the starting structure of the monomer, before MD was 
performed) and were inspected. A summary of the SiteMap analyses is shown in Table 9 
for Monomer-Site2.  
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Figure 35. Conformations of the active site residues 
from the selected snapshots superimposed on the starting 
structure; 35a. Frame 160 superimposed on Frame 0; 
35b. Frame 580 superimposed on Frame 0; 35c. Frame 
820 superimposed on Frame 0; 35d. Frame 1260 
superimposed on Frame 0; 35e. Frame 1700 
superimposed on Frame 0; 35f. Frame 2020 
superimposed on Frame 0; 35g. Frame 2330 
superimposed on Frame 0; 35h. Frame 2760 
superimposed on Frame 0; 35i. Frame 3420 
superimposed on Frame 0; 35j. Frame 4140 
superimposed on Frame 0; 
100 
 
Table 9. SiteMap analyses on the different snapshots of the monomer 
Title 
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Frame 0 1.01 103 1.07 288.81 0.69 0.64 0.81 0.84 0.77 0.98 
Frame 160 0.65 29 0.51 56.94 0.59 0.68 0.97 0.21 1.24 0.25 
Frame 580 1.04 338 1.02 828.35 0.51 0.75 1.00 0.47 1.14 0.81 
Frame 820 0.70 36 0.64 73.06 0.59 0.67 0.89 0.35 0.99 0.28 
Frame 1700 1.03 323 0.99 591.33 0.42 0.75 1.00 0.44 1.22 1.04 
Frame 1260 1.05 343 1.08 735.39 0.51 0.75 0.94 0.78 0.97 0.86 
Frame 2020 1.00 117 0.98 288.81 0.52 0.69 0.91 0.20 1.16 1.32 
Frame 2330 0.99 101 0.89 262.74 0.59 0.69 0.94 0.25 1.43 0.85 
Frame 2760 0.99 143 0.95 338.54 0.58 0.68 0.91 0.27 1.23 0.82 
Frame 3420 0.87 74 0.82 180.08 0.69 0.66 0.86 0.19 1.19 0.82 
Frame 4140 0.92 87 0.91 270.97 0.69 0.64 0.82 0.16 1.08 1.15 
 
 a: used to identify and compare binding sites, a score of 0.8 or higher is generally considered a binding 
site; b: number of site points for the given binding site, a size of 132 or higher is optimal for submicromolar 
sites; c: criterion to decide whether or not the site is druggable, a score greater than 0.98 is considered 
“druggable”; d,e,f: refers to the openness of the binding site to the solvent, lower exposure scores and 
higher enclosure scores are considered better; g: a measure of vdW non bonded interactions of the site 
points with the receptor, average score for submicromolar sites being 1.0; h,i: refers to the hydrophobic and 
hydrophilic properties of the binding site respectively, average scores are 1.0 for submicromolar sites; j: 
refers to the ability of the ligand to donate or accept hydrogen bonds, average score for submicromolar sites 
is 0.76. 
 
Mutagenesis and MM/GBSA studies on Phe87 
To further validate the hydrophobic region involving Phe87 as a hotspot in the 
dimer interface region, alanine mutagenesis studies were performed on the Phe87 residue. 
Mutation of Phe87 to alanine should result in an inactive enzyme since Phe87 is the only 
obvious means of significant communication between the individual monomers.
16
 To 
analyze the importance of this residue at the dimer interface, we mutated one of the 
Phe87 residues to alanine (F87A in one monomer and F87 in the other monomer) and 
performed a 6 ns MD simulation to compare with wild type (WT). Trajectory snapshots 
were collected every 0.5 ps for the WT and the mutant. For WT, the monomer containing 
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the Phe87 (which was mutated to alanine in the mutant) was truncated to a seven-mer 
peptide around Phe87. Similarly, for the mutant, the monomer containing F87A was 
truncated to a seven residue length peptide: residues THAFPSA for wild type and 
THAAPSA for mutated protein (Figure 36).   
The truncated peptide was then prepared using the protein preparation module of 
Schrödinger. GLIDE refinement was performed to get the preparatory files for 
MM/GBSA studies, which requires the protein and peptide to be in a reasonable docked 
conformation.
21
 Unlike other docking options, the ‘refine’ option of GLIDE does not 
dock the ligand but just refines the ligand in the binding site by performing geometry 
optimization of the ligand structure in the field of the receptor. Refinement was 
performed using the standard precision (SP) method in GLIDE,
21
 which performs energy 
minimization for the ligand in field of the receptor. For GLIDE refinement, the truncated 
7-mer peptide was considered as the ligand, the other monomer was considered as the 
receptor and the dimer interface region as the “inhibitor” binding region. MM/GBSA 
calculations were then performed on each of the GLIDE output files. MM/GBSA is an 
all-atom method, which uses molecular mechanics and continuum solvent and 
OPLS_2005 force field to calculate the free energy. In this approach, the free energy is 
calculated according to the equation given below: 
G = Gcomplex – (Greceptor + Gligand) 
MM/GBSA calculates binding free energies similar to MM/PBSA (Molecular Mechanics 
Poisson-Boltzmann Surface Area) which uses the Poisson-Boltzmann model to calculate 
the electrostatic solvation energy as opposed to MM/GBSA, which uses the generalized 
Born model to calculate the electrostatic solvation energy. The accuracy and performance 
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of MM/GBSA vs. MM/PBSA methods was recently reported by Wang et al,
22
 which 
reveals that in most systems, MM/GBSA performs better than MM/PBSA in predicting 
relative binding free energies.
22
 
The binding free energies G) obtained from the MM/GBSA
22, 23
 studies are 
listed in Table 10.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. Truncated seven-mer peptide in the dimer interface for the WT and F87A 
mutant 
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Table 10. Binding energies from MM/GBSA on the mutated (F87A) and non-
mutated protein 
Time (ns) G-F87 G-F87A G
1
Wild Type Mutant
0.00 -96.47 -67.30 -29.17
0.50 -98.61 -82.81 -15.80
1.00 -103.53 -89.61 -13.92
1.50 -90.44 -90.01 -0.43
2.00 -89.94 -40.20 -49.74
2.50 -84.33 -76.40 -7.93
3.00 -80.72 -53.19 -27.53
3.50 -90.19 -74.41 -15.78
4.00 -97.65 -58.72 -38.93
4.50 -97.30 -79.22 -18.08
5.00 -88.36 -78.27 -10.09
5.50 -99.86 -66.39 -33.47
6.00 -95.85 -76.48 -19.37
Average -93.33 -71.77 -21.56  
1 G calculated as the difference in the binding free energies (MMGBSA) between the wild type and mutant (F87A) 
FabH.  
A difference in G between the wild type (WT) and mutant were calculated and 
averaged over the 13 selected snapshots. It can be inferred that the alanine mutation was 
disfavored or the WT was favored over the alanine mutant by -21.56 kcal/mol as 
expected. The negative values for the binding energies and also the difference indicate 
that alanine mutation of Phe87 is not favored. This finding is extremely important in our 
study since the hydrophobic pocket into which residue Phe87 is embedded forms a 
potential inhibitor binding pocket at the dimer interface; therefore it is a potential hot 
spot. 
Docking studies 
Virtual screening provides an interesting way to compare the binding energies of 
different ligands in the field of the receptor. Rigid docking was performed using GLIDE 
SP. As a proof of concept and to further validate the dimer interface as a potential target, 
we performed comparative docking studies with the MDM2 (also referred to as HDM2, 
for the human variant).
8
 Small molecule disruptors have already been reported for 
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MDM2, a protein that heterodimerizes with the tumor suppressor p53.
24
 We initially used 
the Diversity Set I structures available from the National Cancer Institute for this 
comparative study.  Although NCI Diversity Set II has superseded NCI Diversity Set I, 
NCI Diversity Set I still represents the chemical diversity of 140,000 compounds, which 
in turn represents over a quarter million compounds. The structures from the NCI 
Diversity Set I were prepared using Ligprep
25
 in the same way as previously described.
25
 
The prepared ligand set was then docked to the receptors using SP docking and the best 
scoring pose for each compound was selected using an in-built script available from 
Schrödinger. 
Comparative docking studies were performed using Monomer-Site2 (the dimer 
interface region), the MDM2 (PDB ID: 2AXI) receptor, the biological active site 
(Monomer-Site1) and Dimer-site5 (shallow binding region in the dimer interface). 
Although Dimer-Site5 was identified as a potential binding region in the dimer, only the 
monomer was used as the receptor for docking studies, since we were interested in 
inhibiting the dimer formation. The dimer interface (Monomer-Site2) and MDM2 (PDB 
ID: 2AXI) had a very similar distribution of scores (Figure 37). The shallow binding 
region at the dimer interface region (Dimer-Site5) had poor docking scores as expected, 
since it does not have a well-defined pocket. The biological active site (Monomer-Site1) 
on the other hand exhibited better docking scores than the shallow binding site 
(Dimer-Site5) but it showed poorer docking scores than either PPI sites (MDM2 receptor 
and Monomer-Site2). This suggests that induced-fit effects may have to be included for a 
more accurate docking of inhibitors at the biological active site. These data correlate well 
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with the previously described analyses using SiteMap interpreting that dimer interface 
region is a potential binding site (Monomer-Site2). 
Figure 37. Distribution of docking (GLIDE-SP) scores from docking the NCI Diversity 
Set I to MDM2 receptor, biological active site of FabH (Monomer-Site1), dimer interface 
region of FabH (Monomer-Site2) and a shallow binding region at the dimer interface 
(Dimer-Site5).  
 
Docking studies with the NCI Diversity Set II were then performed on the starting 
structure of the monomer, which corresponds to Frame 0 and also representative 
members of each cluster; frames 160, 580, 820, 1260, 1700, 2020, 2330, 2640, 3420, 
4140 corresponding to simulations times of 0.77, 2.78, 3.94, 6.05, 8.16, 9.70, 11.18, 
13.25, 16.42 and 19.87 ns, respectively. Docking was done using the compounds in 
Diversity Set II, available from the National Cancer Institute (NCI) after performing 
ligprep
25
 on the ligand set. The compounds were screened initially using GLIDE standard 
precision docking (SP) and then using extra precision (XP) docking. The poses of the 
ligands were sorted using the best GLIDE XP scores for each ligand. Docking studies on 
the starting structure of the monomer revealed that compounds NSC91529 and 
NSC19803 from the NCI Diversity Set II docked best in the dimer interface region with 
docking scores of -11.75 and -10.20 kcal/mol, respectively, using the XP docking. The 
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ligand interaction energy diagrams showing the interaction of the ligands, NSC91529 and 
NSC19803, with the residues of the receptor are shown in Figure 38.  
 
Figure 38. Ligand interaction diagram of compounds NSC19803 (38a) and NSC91529 
(38b) in the dimer interface binding site; residues are named using their 3-letter amino 
acid code, hydrophobic residues are colored green, polar residues are colored light 
purple, basic residues are colored blue, acidic residues are colored red, hydrogen bonds 
are drawn with a pink line. 
 
 
Figure 39. Compounds NSC91529 (purple) and NSC19803 (blue) bound to FabH 
monomer at the interface region (surface shown as mesh surface in green); Phe87 from 
the other monomer is also shown in brown; the phenyl rings of NSC91529 and 
NSC19803 seem to align with Phe87.  
38a 38b 
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Figure 39 shows the docked pose of the ligands, NSC91529 and NSC19803 in the 
dimer interface region of FabH. The phenyl ring of NSC91529 and pyranose ring 
(monosaccharide unit) of NSC19803 was found to occupy the hydrophobic pocket 
formed by Phe1087 of the other monomer. Interestingly, in the second lowest energy 
pose for NSC19803 (docking score: -10.05 kcal/mol), the trihydroxyphenyl substituent 
occupied the Phe87 binding pocket.   
Representative members of the top clusters as found by DESMOND were also 
used for docking studies, since the monomer would not retain the original conformation 
in the absence of its dimeric partner. Nonetheless, all the snapshots showed high affinity 
for compounds NSC91529 and/or NSC19803 with docking scores ranging between -9.18 
and -9.78 kcal/mol.   
Conclusion and future direction 
In conclusion, we have shown that the dimer interface in FabH could be a potential target 
for designing a new class of inhibitors, which is quintessential to overcome the microbial 
resistance for currently available antibiotics. Although disrupting protein-protein 
interactions is thought to be a difficult task, the recent emergence of PPI disruptors 
suggests the possibility of PPI disruption by small molecules or peptides that target the 
‘hot spots’ in PPI. MD simulations strongly suggest that the monomers through 
dimerization and that the dimeric state is essential for enzyme activity. Solvated 
monomers are not capable of binding to the substrate at the biological active site due to 
large conformational changes leading to a significant change in the 3-D architecture of 
the active site. Any change in conformation at the interface region could alter the shape 
of the long, cylindrical tunnel-like active site, which in turn would not accommodate 
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substrate binding, rendering it inactive. Comparative docking score analysis of the NCI 
Diversity Set I with the FabH dimer interface, a shallow site at the dimer interface, FabH 
catalytic site and the MDM2 receptor (which has inhibitors that disrupt its association 
with its native protein partner p53), further suggests that the dimer interface could be an 
interesting target. This comparative study also proves that the dimer interface in FabH 
behaves very similar to a PPI. On virtually screening compounds from NCI Diversity se 
II, we have shown that compounds NSC91529 and NSC19803 are potentially capable of 
binding at the dimer interface region with good affinity.  
Our future plan is to develop an assay to test the binding of the above said 
compounds.  
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Appendix 1 
 
Figure 1A. Homology model of B. anthracis DXS 
 
 
Figure 1B. Homology model of B. subtilis DXS 
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Figure 1C. Homology model of M. bovis DXS 
 
 
Figure 1D. Homology model of M. tuberculosis DXS 
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Figure 1E. Homology model of T. pallidum DXS 
 
 
Figure 1F. Homology model of V. cholerae DXS 
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Figure 1G. Homology model of Y. pestis DXS 
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Figure 2A. Ramachandran plot for B. anthracis DXS homology model 
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Figure 2B. Ramachandran plot for B. subtilis DXS homology model 
 
 
 120 
 
 
 
 
 
Figure 2C. Ramachandran plot of M. bovis DXS homology model 
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Figure 2D. Ramachandran plot of M. tuberculosis DXS homology model 
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Figure 2E. Ramachandran plot of T. pallidum DXS homology model 
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Figure 2F. Ramachandran plot of V. cholerae DXS homology model 
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Figure 2G. Ramachandran plot of Y. pestis DXS homology model 
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Appendix 2 
 
Table 1A. Hits identified by virtual screening upon docking the NCI Diversity Set II 
to DXS (XP docking scores in kcal/mol) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Title E. coli Title D. radiodurans Title 
P. falciparum 
model Title 
P. vivax 
model 
93033 -11.99 67090 -9.1 114436 -11.47 19803 -12.06 
37433 -11.72 36586 -8.79 80807 -11.09 63865 -12.02 
211356 -10.94 339578 -7.36 63865 -10.24 114436 -11.38 
19803 -10.87 159686 -7.22 117922 -9.76 107022 -11.25 
16736 -10.81 643176 -6.9 407628 -9.72 80807 -11.07 
407628 -10.35 215718 -6.58 19113 -9.68 148832 -10.83 
401077 -10.25 525721 -6.39 19803 -9.68 408734 -10.71 
156563 -10.15 19803 -6.2 408734 -9.67 94914 -10.52 
114436 -10.12 73170 -6.16 94914 -9.66 19113 -10.5 
7524 -9.94 240029 -6.15 40275 -9.64 93033 -10.5 
140873 -9.9 44556 -6.14 25368 -9.6 43344 -10.48 
81750 -9.9 34875 -6.12 60303 -9.6 38743 -10.39 
107022 -9.88 19113 -6.07 81750 -9.57 68971 -10.23 
211094 -9.87 153399 -6.05 30930 -9.54 156939 -10.22 
106863 -9.74 140899 -6.01 159686 -9.53 144982 -10.22 
659436 -9.72 120631 -5.96 38743 -9.49 156957 -10.21 
643176 -9.65 27305 -5.74 215276 -9.33 240029 -10.16 
43409 -9.59 646976 -5.72 361666 -9.3 211094 -10.14 
45383 -9.56 148832 -5.72 339578 -9.29 117922 -10.1 
211340 -9.49 408734 -5.67 659436 -9.21 16631 -10.05 
93945 -9.44 38743 -5.65 211094 -9.21 23895 -10.01 
36586 -9.43 683648 -5.65 659449 -9.05 78623 -10.01 
148832 -9.43 402083 -5.64 42014 -8.91 479 -10 
127133 -9.42 38042 -5.63 23895 -8.9 39984 -9.96 
16722 -9.4 63865 -5.62 211340 -8.84 643176 -9.92 
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Table 1B. GSK-MMV compounds docked to DXS 
(XP docking scores in kcal/mol) 
 
 
 
Title D. radiodurans Title P. falciparum model Title P. vivax-XP 
ligand_503 -17.16 ligand_1222 -16.79 ligand_1755 -15.08 
ligand_504 -16.02 ligand_551 -16.63 ligand_555 -15 
ligand_18 -14.99 ligand_554 -16.46 ligand_2667 -14.98 
ligand_17 -14.73 ligand_690 -16.32 ligand_149 -14.95 
ligand_2156 -14.43 ligand_689 -16.29 ligand_274 -14.9 
ligand_2313 -14.24 ligand_1381 -16.17 ligand_197 -14.78 
ligand_3242 -14.14 ligand_1979 -16.05 ligand_1751 -14.75 
ligand_12 -14.12 ligand_1199 -15.98 ligand_2598 -14.65 
ligand_554 -14.07 ligand_1569 -15.94 ligand_35 -14.65 
ligand_3238 -13.96 ligand_2690 -15.87 ligand_1097 -14.65 
ligand_2699 -13.91 ligand_2477 -15.79 ligand_2102 -14.63 
ligand_1225 -13.84 ligand_1208 -15.68 ligand_1223 -14.6 
ligand_2479 -13.8 ligand_1200 -15.66 ligand_1302 -14.58 
ligand_3006 -13.76 ligand_2611 -15.46 ligand_211 -14.54 
ligand_562 -13.73 ligand_276 -15.46 ligand_2161 -14.54 
ligand_3263 -13.73 ligand_2689 -15.41 ligand_273 -14.46 
ligand_2557 -13.61 ligand_1223 -15.31 ligand_164 -14.45 
ligand_201 -13.56 ligand_1634 -15.31 ligand_1752 -14.39 
ligand_455 -13.53 ligand_694 -15.3 ligand_1226 -14.36 
ligand_2722 -13.52 ligand_1070 -15.22 ligand_695 -14.34 
ligand_116 -13.49 ligand_2612 -15.13 ligand_1818 -14.33 
ligand_1886 -13.49 ligand_1722 -15.11 ligand_2476 -14.32 
ligand_2462 -13.43 ligand_197 -15.08 ligand_689 -14.27 
ligand_645 -13.42 ligand_2476 -15.08 ligand_2479 -14.26 
ligand_1245 -13.42 ligand_2565 -14.84 ligand_276 -14.25 
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Table 1C. Hits identified by virtual screening upon docking the NCI Diversity Set II 
to DXR (XP docking scores in kcal/mol) 
 
Title E. coli Title 
P. vivax 
model  Title 
P. falciparum  
model Title 
Y. pestis  
model 
35676 -8.81 2561 -8.01 89720 -7.48 7606 -8.21 
78623 -8.68 70980 -7.97 37433 -7.2 20586 -8.2 
40383 -8.5 140873 -7.93 62840 -7.02 18473 -8.08 
193528 -8.21 48422 -7.92 34769 -6.83 60037 -8 
91785 -8.12 18473 -7.82 43546 -6.64 106045 -7.41 
43409 -8.01 87504 -7.71 70980 -6.59 129220 -7.37 
9489 -7.88 12227 -7.68 18473 -6.54 48422 -7.16 
87822 -7.82 37433 -7.48 87822 -6.53 109086 -7.14 
87504 -7.73 129220 -7.29 23895 -6.37 479 -7.01 
7745 -7.64 196148 -7.14 118832 -6.36 140873 -6.79 
48422 -7.58 15133 -7.12 56455 -6.33 82769 -6.76 
196148 -7.53 82769 -7.06 81213 -6.32 40383 -6.62 
123141 -7.39 205913 -6.98 48422 -6.21 89720 -6.56 
82769 -7.34 9489 -6.95 3001 -6.02 157767 -6.55 
106581 -7.19 97865 -6.89 601351 -5.86 3001 -6.48 
89720 -7.18 40382 -6.86 94914 -5.8 118832 -6.43 
28371 -7.12 601351 -6.85 36914 -5.72 403374 -6.43 
60202 -7.11 659437 -6.84 372063 -5.71 11470 -6.32 
170621 -7.11 20586 -6.72 60202 -5.52 70980 -6.32 
60266 -7.1 106045 -6.7 41331 -5.52 601351 -6.29 
36520 -6.92 40383 -6.68 45153 -5.51 170621 -6.28 
335504 -6.9 321792 -6.62 144958 -5.5 91785 -6.13 
178873 -6.89 38968 -6.61 40669 -5.49 87504 -6.03 
34769 -6.88 91785 -6.58 39336 -5.42 60202 -6.02 
101809 -6.87 341074 -6.56 91785 -5.4 177866 -5.95 
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Appendix 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3A. Dials plots for phi and psi angles of the interface residues in FabH dimer 
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Figure 3B. Dials plots for phi and psi angles of the interface residues in FabH monomer 
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Figure 3C. Scatter plots for phi and psi angles of the interface residues in FabH dimer 
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Figure 3D. Scatter plots for phi and psi angles of the interface residues in FabH 
monomer 
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Figure 3E. Histogram of GLIDE SP scores for the top 5 NCI Diversity Set I compounds 
docked to MDM2 receptor in comparison with docking to dimer interface (Dimer-Site3), 
biological active site (Monomer-Site1), and a shallow site at the dimer interface (Dimer-
Site5). 
 
 
 
Figure 3F. Histogram of GLIDE SP scores for the top 5 NCI Diversity Set I compounds 
docked to dimer interface (Dimer-Site3) in comparison with docking to MDM2 receptor, 
biological active site (Monomer-Site1), and a shallow site at the dimer interface (Dimer-
Site5). 
-9
-7
-5
-3
-1
402959 35949 319440 208758 168466
G
li
d
e 
S
P
 s
co
re
 (
k
ca
l/
m
o
l)
 
NCI Diversity Set Compounds 
MDM2 Receptor
Biology Active site
Dimer interface
Shallow Site
-9
-7
-5
-3
-1
15226 65933 112751 95910 160319
G
li
d
e 
S
P
 S
co
re
 (
k
ca
l/
m
o
l)
 
NCI Dinersity Set Compounds 
MDM2 Receptor
Biology Active site
Dimer interface
Shallow Site
135 
 
 
Figure 3G. Histogram of GLIDE SP scores for the top 5 NCI Diversity Set I compounds 
docked to biological active site (Monomer-Site1) in comparison with docking to MDM2 
receptor, dimer interface (Dimer-Site3), and a shallow site at the dimer interface (Dimer-
Site5). 
 
 
 
Figure 3H. Histogram of GLIDE SP scores for the top 5 NCI Diversity Set I compounds 
docked to a shallow site at the dimer interface (Dimer-Site5) in comparison with docking 
to MDM2 receptor, dimer interface (Dimer-Site3), and biological active site (Monomer-
Site1). 
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Figure 3I. Different conformations of the residues complementary to Phe87 from the 
selected trajectory snapshots. 
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Figure 3J. Percentage (%) of the first ten Principal components of the monomer and 
dimer.  
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Figure 3K. Residual fluctuations from Principal component analysis on the covariance 
matrix of the monomer and dimer for the 20 ns simulation; PC3, PC4 ad PC5. 
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